[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 2365
1. Wang Y, Xing H, Tian Z, Tang K, Wang J, Xu Z, Rao Q, Wang M, Wang J: Overexpression of Midkine promotes the viability of BA/F3 cells. Biochem Biophys Res Commun; 2009 Jul 3;384(3):341-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Midkine (MK), a heparin-binding growth factor, has been reported to be overexpressed in a variety of human solid tumors.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Nerve Growth Factors / biosynthesis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism
  • [MeSH-minor] Adult. Animals. Apoptosis. Cell Cycle. Cell Proliferation. Cell Survival. Female. Humans. Male. Mice. Middle Aged. bcl-2-Associated X Protein / antagonists & inhibitors. bcl-2-Associated X Protein / metabolism. raf Kinases / metabolism

  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19409372.001).
  • [ISSN] 1090-2104
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MDK protein, human; 0 / Nerve Growth Factors; 0 / bcl-2-Associated X Protein; EC 2.7.11.1 / raf Kinases
  •  go-up   go-down


2. Zhu AX, Ready N, Clark JW, Safran H, Amato A, Salem N, Pace S, He X, Zvereva N, Lynch TJ, Ryan DP, Supko JG: Phase I and pharmacokinetic study of gimatecan given orally once a week for 3 of 4 weeks in patients with advanced solid tumors. Clin Cancer Res; 2009 Jan 1;15(1):374-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I and pharmacokinetic study of gimatecan given orally once a week for 3 of 4 weeks in patients with advanced solid tumors.
  • EXPERIMENTAL DESIGN: Adult patients with advanced solid tumors with good performance status and adequate hematologic, hepatic, and renal function were eligible for the study.
  • This regimen deserves further evaluation to define its antitumor activity in specific tumor types either alone or in combination with other agents.
  • [MeSH-minor] Administration, Oral. Adult. Aged. Drug Administration Schedule. Female. Humans. In Vitro Techniques. Maximum Tolerated Dose. Middle Aged

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19118068.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ST 1481; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


3. Nowakowski GS, McCollum AK, Ames MM, Mandrekar SJ, Reid JM, Adjei AA, Toft DO, Safgren SL, Erlichman C: A phase I trial of twice-weekly 17-allylamino-demethoxy-geldanamycin in patients with advanced cancer. Clin Cancer Res; 2006 Oct 15;12(20 Pt 1):6087-93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EXPERIMENTAL DESIGN: A phase I dose escalating trial in patients with advanced solid tumors was done.
  • Toxicity and tumor responses were evaluated by standard criteria.
  • [MeSH-minor] Adult. HSP70 Heat-Shock Proteins / drug effects. HSP70 Heat-Shock Proteins / metabolism. Humans. Infusions, Intravenous. Life Expectancy. Neoplasm Staging. Patient Selection

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17062684.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA15083; United States / NCI NIH HHS / CA / CA69912; United States / NCI NIH HHS / CA / CA90390; United States / NCRR NIH HHS / RR / RR00585
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzoquinones; 0 / HSP70 Heat-Shock Proteins; 0 / Lactams, Macrocyclic; 4GY0AVT3L4 / tanespimycin
  •  go-up   go-down


Advertisement
4. Shi HR, Wu QH, Suo ZH, Nesland JM: [Correlation between methylation of 5'-CpG islands and inactivation of FHIT gene in cervical cancer]. Ai Zheng; 2005 Jan;24(1):7-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND & OBJECTIVE: Fragile histidine triad (FHIT) gene, a tumor suppressor gene, correlates with tumorigenesis of many solid tumors, and may be inactivated via methylation.
  • [MeSH-major] Acid Anhydride Hydrolases / biosynthesis. CpG Islands / genetics. DNA Methylation. Gene Silencing. Neoplasm Proteins / biosynthesis. Uterine Cervical Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Female. Genes, Tumor Suppressor. Humans. Middle Aged. Neoplasm Staging


5. Ali TZ, Epstein JI: Basal cell carcinoma of the prostate: a clinicopathologic study of 29 cases. Am J Surg Pathol; 2007 May;31(5):697-705
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In 28/29 cases, slides were reviewed and 24 (86%) cases showed more than 1 pattern: adenoid cysticlike (AC-P) pattern and small solid nests with peripheral palisading were the most predominant patterns, each seen in 18 cases (64%).
  • Other patterns included: basal cell hyperplasialike in 9 cases (32%); small tubules occasionally lined by a hyaline rim in 9 cases (32%), with 4 of these cases also demonstrating intermingling cords of cells; and large solid nests in 8 cases (28.5%), 5 of which had central necrosis.
  • Ki67 > or =20% was seen in 13 (56.5%) cases, including all patterns except small solid nests.
  • (2) labeled just the outermost layers in 6/25 (24%) cases; or (3) reacted with only a few scattered cells in 4/25 (16%) cases (3 with large solid nests with central necrosis, 1 with tubules and cords).
  • The most common morphology among those with an aggressive behavior is large solid nests more often with central necrosis, high Ki67%, and less staining with basal cell markers.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Biopsy, Needle. Combined Modality Therapy. Humans. Male. Middle Aged. Mitosis. Neoplasm Recurrence, Local. Retrospective Studies. Transurethral Resection of Prostate

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17460452.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


6. Fukui T, Katayama T, Ito S, Abe T, Hatooka S, Mitsudomi T: Clinicopathological features of small-sized non-small cell lung cancer with mediastinal lymph node metastasis. Lung Cancer; 2009 Dec;66(3):309-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • None of the 14 patients with upper lobe tumor had a positive subcarinal lymph node.
  • CONCLUSIONS: Most small-sized non-small cell lung cancer cases with mediastinal lymph node metastasis were invasive adenocarcinoma with poor differentiation, which usually showed a solid shadow without ground-glass opacity on computed tomography.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / physiopathology. Carcinoma, Squamous Cell / physiopathology. Lung / pathology. Lung Neoplasms / physiopathology. Lymph Nodes / pathology. Tumor Burden
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Differentiation. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness


7. Ghidirim G, Rojnoveanu G, Mishin I, Gutsu E, Iakovleva I: Extra-adrenal nonfunctional retroperitoneal paraganglioma: case report and review of the literature. Int Surg; 2005 Nov-Dec;90(5):275-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An extra-adrenal paraganglioma is a rare tumor derived from the chromaffin cells of sympathetic ganglia.
  • Ultrasonography and computed tomography revealed a solid mass with calcification in center, measuring 7 x 6 x 6 cm, and localized in the left upper para-aortal retroperitoneal region.
  • Tumor was successfully removed through a midline laparotomy incision, and pathological analysis of the surgical specimen revealed a paraganglioma.
  • After 12 months, the patient is still in a good health, asymptomatic, and without evidence of tumor recurrence.
  • [MeSH-minor] Adult. Female. Humans. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16625946.001).
  • [ISSN] 0020-8868
  • [Journal-full-title] International surgery
  • [ISO-abbreviation] Int Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 14
  •  go-up   go-down


8. Oka K, Okane M, Okuno S, Kawasaki T, Yonekawa N, Okano M, Nakayama M: Congenital cervical immature teratoma arising in the left lobe of the thyroid gland. APMIS; 2007 Jan;115(1):75-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 24-year-old Japanese woman had carried a male fetus that was aborted because of a cervical tumor at 20 weeks 5 days of gestation.
  • The cervical tumor weighed 93 g and measured 7.5x5.5x5 cm.
  • The soft tumor was encapsulated by a fibrous layer, was solid with small cysts on the cut surface, and showed a brain-like appearance.
  • The tumor was composed of neoplastic cells derived from the three germ cell layers: ectoderm, mesoderm, and endoderm.
  • Small areas of thyroid tissue were detected in the cervical tumor.
  • Therefore, we concluded that the cervical tumor had arisen in the left lobe of the thyroid gland rather than from the soft tissue of the neck.
  • [MeSH-minor] Abortion, Eugenic. Adult. Female. Fetal Diseases / pathology. Humans. Male. Pregnancy


9. Philip PA, Mahoney MR, Allmer C, Thomas J, Pitot HC, Kim G, Donehower RC, Fitch T, Picus J, Erlichman C: Phase II study of erlotinib in patients with advanced biliary cancer. J Clin Oncol; 2006 Jul 1;24(19):3069-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • HER1/EGFR expression by immunohistochemistry in tumor cells was detected in 29 (81%) of the 36 assessable patients.
  • Three patients had partial response by Response Evaluation Criteria in Solid Tumors Group classification of duration 4, 4, and 14 months, respectively.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Erlotinib Hydrochloride. Female. Humans. Male. Middle Aged. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Survival Analysis

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2007 Mar 20;25(9):1145; author reply 1145-6 [17369582.001]
  • (PMID = 16809731.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CM / N0-1 CM17104
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; 0 / Quinazolines; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


10. Kefford R, Beith JM, Van Hazel GA, Millward M, Trotter JM, Wyld DK, Kusic R, Shreeniwas R, Morganti A, Ballmer A, Segal E, Nayler O, Clozel M: A phase II study of bosentan, a dual endothelin receptor antagonist, as monotherapy in patients with stage IV metastatic melanoma. Invest New Drugs; 2007 Jun;25(3):247-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Data suggest that endothelin may play a role in pathophysiology of melanoma and that the dual endothelin receptor antagonist bosentan may have anti-tumor activity.
  • This multicenter, open-label, single-arm, prospective, proof-of-concept study assessed the effects of bosentan monotherapy (500 mg oral tablets, bid) on tumor response in patients with stage IV metastatic melanoma.
  • Tumor response was assessed at 6-weekly intervals using the Response Evaluation Criteria in Solid Tumors (RECIST).
  • [MeSH-minor] Administration, Oral. Adult. Aged. Australia. Female. Gene Expression Regulation, Neoplastic. Humans. Lymph Nodes / pathology. Male. Middle Aged. Neoplasm Staging. Prospective Studies. RNA, Messenger / metabolism. Receptors, Endothelin / genetics. Receptors, Endothelin / metabolism. Tablets. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Invest Dermatol. 2004 Dec;123(6):1135-9 [15610525.001]
  • [Cites] J Card Fail. 2005 Feb;11(1):12-20 [15704058.001]
  • [Cites] Lancet Oncol. 2003 Dec;4(12):748-59 [14662431.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] J Clin Oncol. 2004 Mar 15;22(6):1118-25 [15020614.001]
  • [Cites] J Clin Invest. 2002 Aug;110(4):443-52 [12189238.001]
  • [Cites] J Invest Dermatol. 1995 Jul;105(1):32-7 [7615973.001]
  • [Cites] Hum Mol Genet. 1995 Nov;4(11):2089-96 [8589685.001]
  • [Cites] Lancet. 2005 Feb 19-25;365(9460):687-701 [15721476.001]
  • [Cites] Cancer Res. 2004 Feb 15;64(4):1436-43 [14973117.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):3892-7 [8632985.001]
  • [Cites] Cell. 1994 Dec 30;79(7):1267-76 [8001159.001]
  • [Cites] Eur Heart J. 2004 Dec;25(24):2243-78 [15589643.001]
  • [Cites] Int J Cancer. 2000 Apr 15;86(2):182-7 [10738244.001]
  • [Cites] Virchows Arch. 2001 May;438(5):485-91 [11407477.001]
  • [Cites] Cell. 1994 Dec 30;79(7):1277-85 [8001160.001]
  • [Cites] Lab Invest. 2000 Nov;80(11):1681-9 [11092528.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(1):158-66 [10623706.001]
  • [Cites] J Clin Oncol. 2001 Aug 15;19(16):3635-48 [11504745.001]
  • [Cites] J Vasc Res. 2001 Nov-Dec;38(6):536-45 [11740152.001]
  • [Cites] Exp Biol Med (Maywood). 2006 Jun;231(6):1111-9 [16741059.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11496-500 [10500205.001]
  • (PMID = 17021960.001).
  • [ISSN] 0167-6997
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Endothelin Receptor Antagonists; 0 / RNA, Messenger; 0 / Receptors, Endothelin; 0 / Sulfonamides; 0 / Tablets; Q326023R30 / bosentan
  •  go-up   go-down


11. Hsiao CC, Huang CC, Sheen JM, Tai MH, Chen CM, Huang LL, Chuang JH: Differential expression of delta-like gene and protein in neuroblastoma, ganglioneuroblastoma and ganglioneuroma. Mod Pathol; 2005 May;18(5):656-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neuroblastoma is an extremely malignant solid tumor in children, characterized by spontaneous differentiation and regression.
  • Three adrenal tissues from children died of diseases other than adrenal tumors and one from an adult with pheochromocytoma were severed as normal and disease controls.
  • Furthermore, higher dlk protein expression in the tumor endothelium than in the endothelium of normal adrenal gland implies that dlk may regulate the endothelial function in neuroblastic tumors.
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Epidermal Growth Factor / genetics. Epidermal Growth Factor / metabolism. Female. Ganglioneuroblastoma / genetics. Ganglioneuroblastoma / metabolism. Ganglioneuroblastoma / pathology. Ganglioneuroma / genetics. Ganglioneuroma / metabolism. Ganglioneuroma / pathology. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. In Situ Hybridization. Infant. Infant, Newborn. Male. Neuroblastoma / genetics. Neuroblastoma / metabolism. Neuroblastoma / pathology. RNA, Messenger / genetics. RNA, Messenger / metabolism

  • Genetic Alliance. consumer health - Neuroblastoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15605081.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glycoproteins; 0 / RNA, Messenger; 62229-50-9 / Epidermal Growth Factor
  •  go-up   go-down


12. Su MC, Hsu C, Kao HL, Jeng YM: CD24 expression is a prognostic factor in intrahepatic cholangiocarcinoma. Cancer Lett; 2006 Apr 8;235(1):34-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CD24, a cell surface protein originally identified in hematological malignancy, were found to be expressed in a large variety of solid tumors.
  • The expression did not significantly correlate the tumor size, stage, lymph node and distant metastasis.
  • In a multivariant analysis, CD24 expression and tumor stage were independent prognostic factors.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Female. Humans. Immunoenzyme Techniques. Lymph Nodes. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Prognosis. Survival Rate


13. Hurrell DP, McCluggage WG: Uterine tumour resembling ovarian sex cord tumour is an immunohistochemically polyphenotypic neoplasm which exhibits coexpression of epithelial, myoid and sex cord markers. J Clin Pathol; 2007 Oct;60(10):1148-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uterine tumour resembling ovarian sex cord tumour is an immunohistochemically polyphenotypic neoplasm which exhibits coexpression of epithelial, myoid and sex cord markers.
  • The tumours were variably composed of solid, corded, trabecular, nested, glandular and retiform arrangements of tumour cells.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Ovarian Neoplasms / diagnosis. Sex Cord-Gonadal Stromal Tumors / diagnosis. Uterine Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Immunophenotyping. Middle Aged. Neoplasm Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2002 Jan;26(1):1-13 [11756764.001]
  • [Cites] Int J Gynecol Pathol. 2001 Oct;20(4):346-52 [11603218.001]
  • [Cites] Am J Surg Pathol. 2002 Nov;26(11):1477-83 [12409724.001]
  • [Cites] J Clin Pathol. 2003 Mar;56(3):221-4 [12610103.001]
  • [Cites] Mod Pathol. 2003 Jun;16(6):584-90 [12808064.001]
  • [Cites] Int J Gynecol Pathol. 2003 Jul;22(3):297-302 [12819400.001]
  • [Cites] Mod Pathol. 2006 Jan;19(1):17-24 [16118629.001]
  • [Cites] Arch Pathol Lab Med. 2006 May;130(5):e74-6 [16683901.001]
  • [Cites] Cesk Patol. 2006 Jul;42(3):145-9 [16955563.001]
  • [Cites] Int J Gynecol Pathol. 2007 Jul;26(3):322-7 [17581419.001]
  • [Cites] Histopathology. 2003 Aug;43(2):144-50 [12877729.001]
  • [Cites] Diagn Mol Pathol. 2003 Sep;12(3):174-80 [12960700.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2003 Sep;11(3):244-9 [12966351.001]
  • [Cites] Gynecol Oncol. 2004 Jan;92(1):347-52 [14751183.001]
  • [Cites] Histopathology. 2004 Feb;44(2):109-15 [14764054.001]
  • [Cites] Int J Gynecol Pathol. 2004 Apr;23(2):97-9 [15084836.001]
  • [Cites] Virchows Arch. 2004 May;444(5):410-4 [15007645.001]
  • [Cites] Int J Gynecol Pathol. 2004 Jul;23(3):241-7 [15213600.001]
  • [Cites] Cancer. 2004 Sep 15;101(6):1455-62 [15316901.001]
  • [Cites] Adv Anat Pathol. 2004 Nov;11(6):310-5 [15505532.001]
  • [Cites] Am J Clin Pathol. 1976 Sep;66(3):512-25 [961630.001]
  • [Cites] Eur J Cell Biol. 1985 May;37:175-90 [3896804.001]
  • [Cites] Hum Pathol. 1986 Jan;17(1):91-4 [3943854.001]
  • [Cites] Am J Surg Pathol. 1992 Oct;16(10):962-8 [1384370.001]
  • [Cites] Cancer Genet Cytogenet. 1992 Oct 1;63(1):43-6 [1423225.001]
  • [Cites] Hum Pathol. 1994 Jan;25(1):60-6 [8314261.001]
  • [Cites] Am J Surg Pathol. 1995 Aug;19(8):927-33 [7611539.001]
  • [Cites] Histopathology. 1995 Oct;27(4):388-90 [8847074.001]
  • [Cites] Am J Surg Pathol. 1997 May;21(5):583-9 [9158684.001]
  • [Cites] Histopathology. 1997 Jul;31(1):67-74 [9253627.001]
  • [Cites] Hum Pathol. 1997 Sep;28(9):1034-8 [9308727.001]
  • [Cites] Hum Pathol. 1997 Nov;28(11):1247-54 [9385929.001]
  • [Cites] Int J Gynecol Pathol. 1998 Jan;17(1):46-53 [9475192.001]
  • [Cites] Int J Gynecol Pathol. 1998 Apr;17(2):97-105 [9553804.001]
  • [Cites] Int J Gynecol Pathol. 1998 Jul;17(3):266-71 [9656124.001]
  • [Cites] Mod Pathol. 1998 Jul;11(7):656-64 [9688187.001]
  • [Cites] Hum Pathol. 1998 Aug;29(8):840-5 [9712426.001]
  • [Cites] Am J Surg Pathol. 1998 Sep;22(9):1078-82 [9737240.001]
  • [Cites] Histopathology. 1999 Apr;34(4):375-6 [10231408.001]
  • [Cites] Hum Pathol. 1999 Jun;30(6):671-9 [10374776.001]
  • [Cites] Histopathology. 2005 Feb;46(2):235-6 [15693901.001]
  • [Cites] Hum Pathol. 2005 Feb;36(2):195-201 [15754297.001]
  • [Cites] J Clin Pathol. 2005 Aug;58(8):888-90 [16049297.001]
  • [Cites] Int J Gynecol Pathol. 2005 Oct;24(4):335-40 [16175078.001]
  • [Cites] J Clin Pathol. 2000 Mar;53(3):206-11 [10823140.001]
  • [Cites] Adv Anat Pathol. 2000 Sep;7(5):257-81 [10976906.001]
  • [Cites] Histopathology. 2001 May;38(5):403-8 [11422476.001]
  • [Cites] Virchows Arch. 2001 Jul;439(1):97-101 [11499847.001]
  • [Cites] Histopathology. 2001 Sep;39(3):273-8 [11532038.001]
  • [Cites] Histopathology. 2002 Sep;41(3):277-9 [12207796.001]
  • (PMID = 17182656.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  • [Other-IDs] NLM/ PMC2014850
  •  go-up   go-down


14. Lam ET, O'Bryant CL, Basche M, Gustafson DL, Serkova N, Baron A, Holden SN, Dancey J, Eckhardt SG, Gore L: A phase I study of gefitinib, capecitabine, and celecoxib in patients with advanced solid tumors. Mol Cancer Ther; 2008 Dec;7(12):3685-94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I study of gefitinib, capecitabine, and celecoxib in patients with advanced solid tumors.
  • This phase I study was designed to determine the maximum tolerated dose (MTD) and toxicity profile of the combination of gefitinib, capecitabine, and celecoxib in patients with advanced solid tumors.
  • Tumor biopsies from 5 patients were analyzed for changes in tumor metabolic activity by nuclear magnetic resonance spectroscopy.
  • The combination of gefitinib and capecitabine is well tolerated and appears to have activity against certain advanced solid tumors, providing a rationale for further evaluation in advanced solid malignancies.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. CELECOXIB .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Med. 1999 Dec;5(12):1418-23 [10581086.001]
  • [Cites] N Engl J Med. 2000 Jun 29;342(26):1946-52 [10874062.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2282-92 [11304782.001]
  • [Cites] Radiographics. 2003 Mar-Apr;23(2):315-40; quiz 533 [12640150.001]
  • [Cites] Clin Cancer Res. 2003 Oct 15;9(13):4735-42 [14581344.001]
  • [Cites] N Engl J Med. 2004 May 20;350(21):2129-39 [15118073.001]
  • [Cites] Science. 2004 Jun 4;304(5676):1497-500 [15118125.001]
  • [Cites] Proc Soc Exp Biol Med. 1983 Feb;172(2):214-8 [6572402.001]
  • [Cites] Annu Rev Cell Biol. 1994;10:251-337 [7888178.001]
  • [Cites] J Biol Chem. 1995 Oct 27;270(43):25915-9 [7592779.001]
  • [Cites] Cell. 1996 Aug 9;86(3):353-64 [8756718.001]
  • [Cites] Cancer Res. 1996 Nov 15;56(22):5125-7 [8912844.001]
  • [Cites] Ann Oncol. 1996 Jan;7(1):95-8 [9081400.001]
  • [Cites] Am J Respir Cell Mol Biol. 1997 Dec;17(6):748-56 [9409562.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1998 Mar;39(3):581-91 [9501870.001]
  • [Cites] Clin Cancer Res. 1995 Jan;1(1):19-31 [9815883.001]
  • [Cites] Radiol Clin North Am. 2005 Jan;43(1):189-204 [15693656.001]
  • [Cites] Kidney Int. 2005 Mar;67(3):1142-51 [15698456.001]
  • [Cites] N Engl J Med. 2005 Mar 17;352(11):1071-80 [15713944.001]
  • [Cites] J Clin Oncol. 2006 Feb 1;24(4):656-62 [16446337.001]
  • [Cites] Anticancer Drugs. 2006 Apr;17(4):401-9 [16549997.001]
  • [Cites] Crit Rev Oncol Hematol. 2006 Apr;58(1):31-45 [16531062.001]
  • [Cites] Clin Breast Cancer. 2006 Feb;6(6):518-24 [16595035.001]
  • [Cites] Am J Clin Oncol. 2006 Apr;29(2):143-7 [16601432.001]
  • [Cites] J Clin Oncol. 2006 Apr 20;24(12):1892-7 [16622264.001]
  • [Cites] Cancer. 2006 May 1;106(9):1917-24 [16568471.001]
  • [Cites] Cancer. 2006 May 15;106(10):2143-7 [16598751.001]
  • [Cites] J Clin Oncol. 2006 Jul 10;24(20):3245-51 [16829648.001]
  • [Cites] Clin Cancer Res. 2006 Oct 1;12(19):5659-67 [17020967.001]
  • [Cites] Pharmacogenomics. 2006 Oct;7(7):1109-23 [17054420.001]
  • [Cites] Clin Breast Cancer. 2006 Oct;7(4):321-5 [17092399.001]
  • [Cites] Am J Clin Oncol. 2006 Dec;29(6):576-82 [17148994.001]
  • [Cites] Eur J Cancer. 2006 Dec;42(18):3161-8 [17098421.001]
  • [Cites] Head Neck. 2007 Jan;29(1):47-51 [17103405.001]
  • [Cites] Ann Oncol. 2007 Feb;18(2):305-10 [17079693.001]
  • [Cites] Cancer Res. 2007 Mar 1;67(5):2150-9 [17332345.001]
  • (PMID = 19074845.001).
  • [ISSN] 1535-7163
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA106349-05; United States / NCI NIH HHS / CA / R21 CA108624; United States / NCI NIH HHS / CA / K24 CA106349-05; United States / NCI NIH HHS / CA / U01 CA099176; United States / NCI NIH HHS / CA / P30 CA046934; United States / NCI NIH HHS / CA / K24 CA106349
  • [Publication-type] Clinical Trial, Phase I; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Pyrazoles; 0 / Quinazolines; 0 / Sulfonamides; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; JCX84Q7J1L / Celecoxib; S65743JHBS / gefitinib; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ NIHMS169576; NLM/ PMC2813692
  •  go-up   go-down


15. Alcázar JL, Rodriguez D, Royo P, Galván R, Ajossa S, Guerriero S: Intraobserver and interobserver reproducibility of 3-dimensional power Doppler vascular indices in assessment of solid and cystic-solid adnexal masses. J Ultrasound Med; 2008 Jan;27(1):1-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraobserver and interobserver reproducibility of 3-dimensional power Doppler vascular indices in assessment of solid and cystic-solid adnexal masses.
  • OBJECTIVE: The purpose of this study was to assess the intraobserver and interobserver reproducibility of 3-dimensional (3D) power Doppler angiography-derived vascular indices in evaluation of vascularized solid and cystic-solid adnexal masses.
  • METHODS: Stored 3D power Doppler angiographic volume data from 12 consecutive women with a diagnosis of a complex adnexal mass (6 cystic-solid and 6 solid) evaluated and treated at our institution were retrieved from our database for analysis.
  • Calculations were performed offline in a computer using Virtual Organ Computer-Aided Analysis software (plane A, 9 degrees rotation step) to assess volume and vascularization (vascularization index, flow index, and vascularization-flow index) from solid areas within the tumor.
  • [MeSH-minor] Adnexa Uteri / blood supply. Adnexa Uteri / ultrasonography. Adult. Aged. Female. Humans. Imaging, Three-Dimensional. Middle Aged. Observer Variation. Ovarian Cysts / ultrasonography. Ovarian Neoplasms / ultrasonography. Predictive Value of Tests. Reproducibility of Results. Statistics, Nonparametric

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18096724.001).
  • [ISSN] 0278-4297
  • [Journal-full-title] Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
  • [ISO-abbreviation] J Ultrasound Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Charest A, Wilker EW, McLaughlin ME, Lane K, Gowda R, Coven S, McMahon K, Kovach S, Feng Y, Yaffe MB, Jacks T, Housman D: ROS fusion tyrosine kinase activates a SH2 domain-containing phosphatase-2/phosphatidylinositol 3-kinase/mammalian target of rapamycin signaling axis to form glioblastoma in mice. Cancer Res; 2006 Aug 1;66(15):7473-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here, we show that a glioblastoma-associated, ligand-independent rearrangement product of ROS (FIG-ROS) cooperates with loss of the tumor suppressor gene locus Ink4a;Arf to produce glioblastomas in the mouse.
  • We show that this FIG-ROS-mediated tumor formation in vivo parallels the activation of the tyrosine phosphatase SH2 domain-containing phosphatase-2 (SHP-2) and a phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling axis in tumors and tumor-derived cell lines.
  • We have established a fully penetrant preclinical model for adult onset of glioblastoma multiforme in keeping with major genetic events observed in the human disease.
  • These findings provide novel and important insights into the role of ROS and SHP-2 function in solid tumor biology and set the stage for preclinical testing of targeted therapeutic approaches.
  • [MeSH-minor] Animals. Astrocytoma / enzymology. Astrocytoma / metabolism. Astrocytoma / pathology. Cyclin-Dependent Kinase Inhibitor p16 / deficiency. Cyclin-Dependent Kinase Inhibitor p16 / genetics. Enzyme Activation. Intracellular Signaling Peptides and Proteins / metabolism. Mice. Protein Phosphatase 2. Protein Tyrosine Phosphatase, Non-Receptor Type 11. Protein Tyrosine Phosphatases / metabolism. Proto-Oncogene Proteins c-akt / metabolism. Recombinant Fusion Proteins / biosynthesis. Recombinant Fusion Proteins / genetics. Recombinant Fusion Proteins / metabolism. SH2 Domain-Containing Protein Tyrosine Phosphatases. Signal Transduction. TOR Serine-Threonine Kinases. Tumor Suppressor Protein p14ARF / deficiency. Tumor Suppressor Protein p14ARF / genetics. src Homology Domains

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16885344.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA 042063; United States / NIGMS NIH HHS / GM / R01 GM 060594
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cdkn2a protein, mouse; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Intracellular Signaling Peptides and Proteins; 0 / Proto-Oncogene Proteins; 0 / Recombinant Fusion Proteins; 0 / Tumor Suppressor Protein p14ARF; EC 2.7.- / Protein Kinases; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.1.1 / mTOR protein, mouse; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / ROS1 protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 3.1.3.16 / Protein Phosphatase 2; EC 3.1.3.48 / PTPN11 protein, human; EC 3.1.3.48 / Protein Tyrosine Phosphatase, Non-Receptor Type 11; EC 3.1.3.48 / Protein Tyrosine Phosphatases; EC 3.1.3.48 / Ptpn11 protein, mouse; EC 3.1.3.48 / SH2 Domain-Containing Protein Tyrosine Phosphatases
  •  go-up   go-down


17. Wakabayashi T, Kayama T, Nishikawa R, Takahashi H, Yoshimine T, Hashimoto N, Aoki T, Kurisu K, Natsume A, Ogura M, Yoshida J: A multicenter phase I trial of interferon-beta and temozolomide combination therapy for high-grade gliomas (INTEGRA Study). Jpn J Clin Oncol; 2008 Oct;38(10):715-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In addition, objective tumor response will be evaluated in a subpopulation of patients with the measurable disease.
  • The reduction rate of tumor will be calculated according to Response Evaluation Criteria In Solid Tumors for measurable tumors as determined by magnetic resonance imaging.
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Dacarbazine / administration & dosage. Dacarbazine / analogs & derivatives. Follow-Up Studies. Humans. Interferon-beta / administration & dosage. Magnetic Resonance Imaging. Middle Aged. Neoplasm Staging. Prognosis. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18845525.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 77238-31-4 / Interferon-beta; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


18. Rodríguez-Peláez M, Menéndez De Llano R, Varela M: [Benign liver tumors]. Gastroenterol Hepatol; 2010 May;33(5):391-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most common benign solid liver tumor is hemangioma followed by focal nodular hyperplasia; the most common cystic tumor is the simple cyst.
  • [MeSH-minor] Adult. Biomarkers, Tumor. Carcinoma, Hepatocellular / diagnosis. Child. Diagnosis, Differential. Diagnostic Imaging. Female. Hepatectomy. Humans. Incidental Findings. Male. Mutation

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Gastroenterol Hepatol. 2010 Jun-Jul;33(6):473-4; author reply 474-5 [20537429.001]
  • (PMID = 20096966.001).
  • [ISSN] 0210-5705
  • [Journal-full-title] Gastroenterología y hepatología
  • [ISO-abbreviation] Gastroenterol Hepatol
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 31
  •  go-up   go-down


19. Iwasaki T, Murakami M, Sugisaki C, Sobue S, Ohashi H, Asano H, Suzuki M, Nakamura S, Ito M, Murate T: Characterization of myelodysplastic syndrome and aplastic anemia by immunostaining of p53 and hemoglobin F and karyotype analysis: differential diagnosis between refractory anemia and aplastic anemia. Pathol Int; 2008 Jun;58(6):353-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • P53 mutation has been reported in various solid tumors, acute leukemia and myelodysplastic syndrome (MDS), but the diagnostic significance of p53 in MDS remains to be determined.
  • [MeSH-major] Anemia, Aplastic / diagnosis. Anemia, Refractory / diagnosis. Fetal Hemoglobin / metabolism. Myelodysplastic Syndromes / diagnosis. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers / metabolism. Bone Marrow Cells. DNA Mutational Analysis. DNA, Neoplasm. Diagnosis, Differential. Female. Fluorescent Antibody Technique, Indirect. Humans. Karyotyping. Male. Middle Aged. Mutation


20. Watanabe H, Watanabe T, Suzuya H, Wakata Y, Kaneko M, Onishi T, Okamoto Y, Abe T, Kawano Y, Kagami S, Takaue Y: Peripheral blood stem cell mobilization by granulocyte colony-stimulating factor alone and engraftment kinetics following autologous transplantation in children and adolescents with solid tumor. Bone Marrow Transplant; 2006 Apr;37(7):661-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peripheral blood stem cell mobilization by granulocyte colony-stimulating factor alone and engraftment kinetics following autologous transplantation in children and adolescents with solid tumor.
  • In 56 pediatric and adolescent patients (median age 7 years, range 1-21) with various solid tumors, peripheral blood stem cells (PBSC) were mobilized with granulocyte colony-stimulating factor (G-CSF) alone, and the yields of PBSC and engraftment kinetics following autologous peripheral blood stem cell transplantation (PBSCT) were evaluated retrospectively.
  • In summary, mobilization with G-CSF alone can mobilize sufficient CD34+ cells for successful autografting and sustained hematological reconstitution in pediatric and adolescent patients with solid tumors, and even in heavily pre-treated patients.
  • [MeSH-minor] Adolescent. Adult. Antigens, CD34 / blood. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Female. Graft Survival. Humans. Infant. Kinetics. Male. Retrospective Studies. Transplantation Conditioning. Transplantation, Autologous. Transplantation, Homologous. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16489358.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD34; 143011-72-7 / Granulocyte Colony-Stimulating Factor
  •  go-up   go-down


21. Fraser CJ, Weigel BJ, Perentesis JP, Dusenbery KE, DeFor TE, Baker KS, Verneris MR: Autologous stem cell transplantation for high-risk Ewing's sarcoma and other pediatric solid tumors. Bone Marrow Transplant; 2006 Jan;37(2):175-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous stem cell transplantation for high-risk Ewing's sarcoma and other pediatric solid tumors.
  • The prognosis for many pediatric and young adult patients with solid tumors that have metastasized at the time of diagnosis or have relapsed after therapy remains very poor.
  • Patients with a diagnosis of Ewing's sarcoma (ES) or desmoplastic small round cell tumor (DSRCT) had significantly better survival than those with other diagnoses with estimated 3-year OS of 54% (95% CI: 29-79%) for this group of patients (P = 0.03).
  • [MeSH-major] Bone Neoplasms / mortality. Bone Neoplasms / therapy. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / therapy. Sarcoma, Ewing / mortality. Sarcoma, Ewing / therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Disease-Free Survival. Female. Fibroma, Desmoplastic / complications. Fibroma, Desmoplastic / mortality. Fibroma, Desmoplastic / pathology. Fibroma, Desmoplastic / therapy. Follow-Up Studies. Hepatic Veno-Occlusive Disease / etiology. Hepatic Veno-Occlusive Disease / mortality. Humans. Male. Risk Factors. Stem Cell Transplantation / methods. Stem Cell Transplantation / mortality. Survival Rate. Transplantation, Autologous

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16273111.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


22. Ray MR, Roychoudhury S, Mukherjee S, Siddique S, Banerjee M, Akolkar AB, Sengupta B, Lahiri T: Airway inflammation and upregulation of beta2 Mac-1 integrin expression on circulating leukocytes of female ragpickers in India. J Occup Health; 2009;51(3):232-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: Over one million ragpickers collect and sale recyclable materials from municipal solid wastes (MSW) in India for a living.
  • The concentrations of pro-inflammatory cytokine tumor necrosis factor-alpha (TNF-alpha) and chemokine interleukin-8 (IL-8) were measured in plasma by enzyme-linked immunosorbent assay.
  • [MeSH-minor] Adult. Female. Garbage. Humans. India. Middle Aged. P-Selectin / blood. P-Selectin / metabolism. Poverty. Tumor Necrosis Factor-alpha / blood. Tumor Necrosis Factor-alpha / metabolism

  • MedlinePlus Health Information. consumer health - Acute Bronchitis.
  • MedlinePlus Health Information. consumer health - Occupational Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19372628.001).
  • [ISSN] 1348-9585
  • [Journal-full-title] Journal of occupational health
  • [ISO-abbreviation] J Occup Health
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Macrophage-1 Antigen; 0 / P-Selectin; 0 / Tumor Necrosis Factor-alpha
  •  go-up   go-down


23. Fong PC, Yap TA, Boss DS, Carden CP, Mergui-Roelvink M, Gourley C, De Greve J, Lubinski J, Shanley S, Messiou C, A'Hern R, Tutt A, Ashworth A, Stone J, Carmichael J, Schellens JH, de Bono JS, Kaye SB: Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol; 2010 May 20;28(15):2512-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Selective tumor cell cytotoxicity can be achieved through a synthetic lethal strategy using poly(ADP)-ribose polymerase (PARP) inhibitor therapy in BRCA1/2 mutation carriers in whom tumor cells have defective homologous recombination (HR) DNA repair.
  • Twenty (40%; 95% CI, 26% to 55%) achieved Response Evaluation Criteria in Solid Tumors (RECIST) complete or partial responses and/or tumor marker (CA125) responses, and three (6.0%) maintained RECIST disease stabilization for more than 4 months, giving an overall clinical benefit rate of 46% (95% CI, 32% to 61%).
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Line, Tumor. Cohort Studies. Dose-Response Relationship, Drug. Drug Resistance, Neoplasm. Fallopian Tube Neoplasms / drug therapy. Fallopian Tube Neoplasms / enzymology. Fallopian Tube Neoplasms / genetics. Fallopian Tube Neoplasms / pathology. Female. Genes, BRCA1. Genes, BRCA2. Germ-Line Mutation. Humans. Middle Aged. Neoplasm Staging. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / enzymology. Peritoneal Neoplasms / genetics. Peritoneal Neoplasms / pathology. Pharmacogenetics. Poly(ADP-ribose) Polymerases / genetics


24. Dahut WL, Aragon-Ching JB, Woo S, Tohnya TM, Gulley JL, Arlen PM, Wright JJ, Ventiz J, Figg WD: Phase I study of oral lenalidomide in patients with refractory metastatic cancer. J Clin Pharmacol; 2009 Jun;49(6):650-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Objectives of this study were to determine the maximum tolerated dose and to characterize the side effect profile and pharmacokinetics of lenalidomide in patients with advanced refractory solid tumors.
  • A total of 45 patients with 8 different tumor types were accrued.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Neoplasm Metastasis / drug therapy. Neoplasms / drug therapy. Thalidomide / analogs & derivatives
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Oral cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1999 Nov 18;341(21):1565-71 [10564685.001]
  • [Cites] J Clin Oncol. 2008 Mar 20;26(9):1544-52 [18285605.001]
  • [Cites] J Biochem Mol Toxicol. 2000;14(3):140-7 [10711629.001]
  • [Cites] J Clin Pharmacol. 2001 Jun;41(6):662-7 [11402635.001]
  • [Cites] Clin Cancer Res. 2001 Jul;7(7):1888-93 [11448901.001]
  • [Cites] Blood. 2002 Nov 1;100(9):3063-7 [12384400.001]
  • [Cites] Br J Cancer. 2002 Nov 4;87(10):1166-72 [12402158.001]
  • [Cites] Br J Cancer. 2004 Mar 8;90(5):955-61 [14997189.001]
  • [Cites] Semin Hematol. 2003 Oct;40(4 Suppl 4):33-8 [15015894.001]
  • [Cites] Nat Rev Cancer. 2004 Apr;4(4):314-22 [15057291.001]
  • [Cites] J Clin Oncol. 2004 Jul 1;22(13):2532-9 [15226321.001]
  • [Cites] Nephron. 1976;16(1):31-41 [1244564.001]
  • [Cites] Sci Am. 1976 May;234(5):58-64, 70-3 [1273568.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):4082-5 [7513432.001]
  • [Cites] Mol Med. 1996 Jul;2(4):506-15 [8827720.001]
  • [Cites] Bioorg Med Chem Lett. 1999 Jun 7;9(11):1625-30 [10386948.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2004 Nov 25;811(2):135-41 [15522712.001]
  • [Cites] N Engl J Med. 2005 Feb 10;352(6):549-57 [15703420.001]
  • [Cites] Microvasc Res. 2005 Jan;69(1-2):56-63 [15797261.001]
  • [Cites] Blood. 2006 Nov 15;108(10):3458-64 [16840727.001]
  • [Cites] Cancer. 2006 Dec 1;107(11):2609-16 [17075879.001]
  • [Cites] J Clin Pharmacol. 2007 Dec;47(12):1466-75 [17954615.001]
  • [Cites] Clin Cancer Res. 2007 Dec 1;13(23):7101-6 [18056189.001]
  • [Cites] Leuk Lymphoma. 2008 Feb;49(2):346-9 [18231924.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(4):708-15 [10673511.001]
  • (PMID = 19451403.001).
  • [ISSN] 0091-2700
  • [Journal-full-title] Journal of clinical pharmacology
  • [ISO-abbreviation] J Clin Pharmacol
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 SC006538-14
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 4Z8R6ORS6L / Thalidomide; F0P408N6V4 / lenalidomide
  • [Other-IDs] NLM/ NIHMS163913; NLM/ PMC2808857
  •  go-up   go-down


25. Wörns MA, Weinmann A, Pfingst K, Schulte-Sasse C, Messow CM, Schulze-Bergkamen H, Teufel A, Schuchmann M, Kanzler S, Düber C, Otto G, Galle PR: Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis. J Clin Gastroenterol; 2009 May-Jun;43(5):489-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Adverse events (AEs) were graded using Common Toxicity Criteria version 3.0, tumor response was assessed according to Response Evaluation Criteria in Solid Tumors.
  • During treatment period (median 2.2 mo), therapy was discontinued in 61.8% of patients due to tumor progression (32.3%), death (17.6%), AEs (8.8%), or noncompliance (2.9%).
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Niacinamide / analogs & derivatives. Patient Selection. Phenylurea Compounds. Prospective Studies. Risk Assessment. Severity of Illness Index. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Gastroenterol. 2009 May-Jun;43(5):389-90 [19564813.001]
  • (PMID = 19247201.001).
  • [ISSN] 1539-2031
  • [Journal-full-title] Journal of clinical gastroenterology
  • [ISO-abbreviation] J. Clin. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Protein Kinase Inhibitors; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib
  •  go-up   go-down


26. Glazebrook KN, Reynolds C, Smith RL, Gimenez EI, Boughey JC: Adenoid cystic carcinoma of the breast. AJR Am J Roentgenol; 2010 May;194(5):1391-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MRI (n = 5)--because of better soft-tissue contrast and dedicated, multiplanar breast sequences--helped show the extent of the tumor, particularly if dense breast tissue obscured the mass on CT.
  • Two cases with subtle sonographic findings were better delineated on MRI because of tumor enhancement.
  • The solid variant showed increased signal intensity on T2-weighted imaging.
  • CONCLUSION: Recognition of ACC is important to avoid delay in diagnosis because this tumor has a good prognosis with rare metastases to axillary lymph nodes.
  • [MeSH-minor] Adult. Aged. Female. Humans. Incidence. Middle Aged. Minnesota / epidemiology. Reproducibility of Results. Risk Assessment. Risk Factors. Sensitivity and Specificity. Young Adult


27. Campone M, Isambert N, Bourbouloux E, Maury S, Monin-Baroille P, Berille J, Fumoleau P: Phase I dose-escalation study of a novel antitumor agent, SR271425, administered intravenously in split doses (d1-d2-d3) in patients with refractory solid tumors. Cancer Chemother Pharmacol; 2007 Apr;59(5):689-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I dose-escalation study of a novel antitumor agent, SR271425, administered intravenously in split doses (d1-d2-d3) in patients with refractory solid tumors.
  • METHODS: Patient with advanced solid tumors, adequate bone marrow, hepatic, renal function and on specific cardiac criteria were eligible and "3 + 3" design was used for dose escalation.
  • Main tumor types were brain, breast, gynecological, and urological.
  • [MeSH-minor] Adult. Aged. Area Under Curve. Chromatography, Liquid. Dose-Response Relationship, Drug. Drug Resistance, Neoplasm. Electrocardiography / drug effects. Female. Half-Life. Humans. Injections, Intravenous. Male. Mass Spectrometry. Middle Aged

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17031647.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / SR 271425; 0 / Thioxanthenes
  •  go-up   go-down


28. Achimaş-Cadariu P, Irimie A, Achimaş-Cadariu L, Neagoe I, Buiga R: Could serologic and ultrasonographic indexes be useful for therapeutic decisions in patients with ovarian cancer? Chirurgia (Bucur); 2009 May-Jun;104(3):287-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Only two ultrasonographic predictors: Multilocular Solid Masses insight the tumor and Diastolic Notch fulfilled the required values in order to be considered independent predictors for disease free interval.
  • [MeSH-major] Biomarkers, Tumor / blood. Ovarian Neoplasms / blood. Ovarian Neoplasms / ultrasonography
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Agents / therapeutic use. CA-125 Antigen / blood. Chemotherapy, Adjuvant. Female. Humans. Middle Aged. Multivariate Analysis. Platelet-Derived Growth Factor / metabolism. Predictive Value of Tests. Prognosis. Prospective Studies. Research Design. Risk Assessment. Sampling Studies. Survival Analysis

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19601460.001).
  • [ISSN] 1221-9118
  • [Journal-full-title] Chirurgia (Bucharest, Romania : 1990)
  • [ISO-abbreviation] Chirurgia (Bucur)
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / Platelet-Derived Growth Factor
  •  go-up   go-down


29. Bael TE, Peterson BL, Gollob JA: Phase II trial of arsenic trioxide and ascorbic acid with temozolomide in patients with metastatic melanoma with or without central nervous system metastases. Melanoma Res; 2008 Apr;18(2):147-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This is the first trial combining ATO with chemotherapy in a solid tumor.
  • [MeSH-minor] Adult. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Agents, Alkylating / adverse effects. Antineoplastic Agents, Alkylating / therapeutic use. Antioxidants / administration & dosage. Antioxidants / adverse effects. Antioxidants / therapeutic use. Female. Humans. Male. Middle Aged. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Vitamin C.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • Hazardous Substances Data Bank. Sodium ascorbate .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. L-Ascorbic Acid .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18337652.001).
  • [ISSN] 0960-8931
  • [Journal-full-title] Melanoma research
  • [ISO-abbreviation] Melanoma Res.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Alkylating; 0 / Antioxidants; 0 / Arsenicals; 0 / Oxides; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; PQ6CK8PD0R / Ascorbic Acid; S7V92P67HO / arsenic trioxide
  •  go-up   go-down


30. Chang RF, Huang SF, Moon WK, Lee YH, Chen DR: Solid breast masses: neural network analysis of vascular features at three-dimensional power Doppler US for benign or malignant classification. Radiology; 2007 Apr;243(1):56-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solid breast masses: neural network analysis of vascular features at three-dimensional power Doppler US for benign or malignant classification.
  • PURPOSE: To retrospectively evaluate the accuracy of neural network analysis of tumor vascular features at three-dimensional (3D) power Doppler ultrasonography (US) for classification of breast tumors as benign or malignant, with histologic findings as the reference standard.
  • Three-dimensional power Doppler US images of 221 solid breast masses (110 benign, 111 malignant) were obtained in 221 women (mean age, 46 years; range, 25-71 years).
  • [MeSH-minor] Adult. Aged. Blood Vessels / anatomy & histology. Blood Vessels / ultrasonography. Female. Humans. Middle Aged. ROC Curve. Retrospective Studies. Sensitivity and Specificity. Ultrasonography, Doppler

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17312276.001).
  • [ISSN] 0033-8419
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Reddy PS, Burroughs KD, Hales LM, Ganesh S, Jones BH, Idamakanti N, Hay C, Li SS, Skele KL, Vasko AJ, Yang J, Watkins DN, Rudin CM, Hallenbeck PL: Seneca Valley virus, a systemically deliverable oncolytic picornavirus, and the treatment of neuroendocrine cancers. J Natl Cancer Inst; 2007 Nov 07;99(21):1623-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, the treatment of metastatic disease with oncolytic viruses has been challenging due to the inactivation of viruses by components of human blood and/or to inadequate tumor selectivity.
  • METHODS: We determined the cytolytic potential and selectivity of Seneca Valley Virus-001 (SVV-001), a newly discovered native picornavirus, in neuroendocrine and pediatric tumor cell lines and normal cells.
  • RESULTS: Cell lines derived from small-cell lung cancers and solid pediatric cancers were at least 10,000-fold more sensitive to the cytolytic activity of SVV-001 than were any of the adult normal human cells tested.
  • CONCLUSIONS: SVV-001 has potent cytolytic activity and high selectivity for tumor cell lines having neuroendocrine properties versus adult normal cells.
  • [MeSH-minor] Animals. Carcinoma, Small Cell / therapy. Cell Line, Tumor. Disease Models, Animal. Hemagglutination Tests. Humans. Immunohistochemistry. Injections, Intravenous. Lung Neoplasms / therapy. Mice. Mice, Nude. Research Design. Retinoblastoma / therapy. Transplantation, Heterologous

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • SciCrunch. DrugBank: Data: Chemical .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17971529.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA006973
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


32. Krupkova O Jr, Loja T, Zambo I, Veselska R: Nestin expression in human tumors and tumor cell lines. Neoplasma; 2010;57(4):291-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nestin expression in human tumors and tumor cell lines.
  • The aim of this review is to summarize current knowledge on nestin expression in human tumors and corresponding tumor cell lines.
  • This protein has been observed in the subventricular zone of the adult mammalian brain, where neurogenesis is localized.
  • Nestin expression has also been detected in various types of human solid tumors, as well as in the corresponding established cell lines.
  • Another aim of this review is to summarize recent findings on the intracellular localization of nestin in human tumor cells, especially with regard to the possible correlation between nestin expression and the malignant phenotype of transformed cells.
  • [MeSH-minor] Animals. Cell Line, Tumor. Endothelium, Vascular / metabolism. Humans. Nestin

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20429619.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 0 / Intermediate Filament Proteins; 0 / NES protein, human; 0 / Nerve Tissue Proteins; 0 / Nestin
  • [Number-of-references] 86
  •  go-up   go-down


33. Loges S, Clausen H, Reichelt U, Bubenheim M, Erbersdobler A, Schurr P, Yekebas E, Schuch G, Izbicki J, Pantel K, Bokemeyer C, Fiedler W: Determination of microvessel density by quantitative real-time PCR in esophageal cancer: correlation with histologic methods, angiogenic growth factor expression, and lymph node metastasis. Clin Cancer Res; 2007 Jan 1;13(1):76-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Angiogenesis and lymphangiogenesis are important steps in tumor growth and dissemination and are of prognostic importance in solid tumors.
  • Interestingly, the extent of angiogenesis and lymphangiogenesis was not related in individual tumor samples.
  • [MeSH-minor] Adult. Aged. Antigens, CD / biosynthesis. Antigens, CD146 / biosynthesis. Cadherins / biosynthesis. DNA Primers / chemistry. Female. Humans. Immunohistochemistry. Male. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17200341.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD146; 0 / Cadherins; 0 / DNA Primers; 0 / cadherin 5
  •  go-up   go-down


34. Milowsky MI, Nanus DM, Kostakoglu L, Sheehan CE, Vallabhajosula S, Goldsmith SJ, Ross JS, Bander NH: Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors. J Clin Oncol; 2007 Feb 10;25(5):540-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors.
  • PURPOSE: Based on prostate-specific membrane antigen (PSMA) expression on the vasculature of solid tumors, we performed a phase I trial of antibody J591, targeting the extracellular domain of PSMA, in patients with advanced solid tumor malignancies.
  • PATIENTS AND METHODS: Patients had advanced solid tumors previously shown to express PSMA on the neovasculature.
  • Immunohistochemistry assessed PSMA expression in tumor tissues.
  • Seven of 10 patient specimens available for immunohistochemical assessment of PSMA expression in tumor-associated vasculature demonstrated PSMA staining.
  • CONCLUSION: Acceptable toxicity and excellent targeting of known sites of metastases were demonstrated in patients with multiple solid tumor types, highlighting a potential role for the anti-PSMA antibody J591 as a vascular-targeting agent.
  • [MeSH-major] Antibodies, Monoclonal / pharmacokinetics. Antigens, Neoplasm / immunology. Antigens, Surface / immunology. Antineoplastic Agents / pharmacokinetics. Glutamate Carboxypeptidase II / immunology. Neoplasms / drug therapy. Neoplasms / metabolism. Neovascularization, Pathologic / drug therapy. Neovascularization, Pathologic / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Drug Delivery Systems. Endothelium, Vascular / immunology. Endothelium, Vascular / metabolism. Female. Humans. Immunohistochemistry. Male. Middle Aged. New York City. Radiopharmaceuticals / pharmacokinetics. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17290063.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / M01RR00047
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, Neoplasm; 0 / Antigens, Surface; 0 / Antineoplastic Agents; 0 / J591 monoclonal antibody; 0 / Radiopharmaceuticals; EC 3.4.17.21 / Glutamate Carboxypeptidase II; EC 3.4.17.21 / glutamate carboxypeptidase II, human
  •  go-up   go-down


35. Rini BI, Garcia JA, Cooney MM, Elson P, Tyler A, Beatty K, Bokar J, Mekhail T, Bukowski RM, Budd GT, Triozzi P, Borden E, Ivy P, Chen HX, Dolwati A, Dreicer R: A phase I study of sunitinib plus bevacizumab in advanced solid tumors. Clin Cancer Res; 2009 Oct 1;15(19):6277-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I study of sunitinib plus bevacizumab in advanced solid tumors.
  • EXPERIMENTAL DESIGN: Patients with advanced solid tumors were treated on a 3+3 trial design.
  • Seven patients had a confirmed Response Evaluation Criteria in Solid Tumors-defined partial response (18%; 95% confidence interval, 8-34%).
  • Nineteen of the 32 patients with a postbaseline scan (59%) had at least some reduction in overall tumor burden (median, 32%; range, 3-73%).
  • CONCLUSIONS: The combination of sunitinib and bevacizumab in patients with advanced solid tumors is feasible, albeit with toxicity at higher dose levels and requiring dose modification with continued therapy.
  • Antitumor activity was observed across multiple solid tumors.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] J Clin Oncol. 2009 Mar 20;27(9):1432-9 [19224847.001]
  • [Cites] J Clin Oncol. 2002 Nov 1;20(21):4368-80 [12409337.001]
  • [Cites] N Engl J Med. 2003 Jul 31;349(5):427-34 [12890841.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2335-42 [15175435.001]
  • [Cites] Cancer Res. 1997 Oct 15;57(20):4593-9 [9377574.001]
  • [Cites] J Clin Oncol. 2006 Jan 1;24(1):16-24 [16330672.001]
  • [Cites] JAMA. 2006 Jun 7;295(21):2516-24 [16757724.001]
  • [Cites] Lancet. 2006 Oct 14;368(9544):1329-38 [17046465.001]
  • [Cites] N Engl J Med. 2006 Dec 14;355(24):2542-50 [17167137.001]
  • [Cites] J Natl Cancer Inst. 2007 Jan 3;99(1):81-3 [17202116.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):115-24 [17215529.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):125-34 [17215530.001]
  • [Cites] Lancet Oncol. 2007 Feb;8(2):177-8 [17267332.001]
  • [Cites] J Transl Med. 2007;5:32 [17605814.001]
  • [Cites] Lancet. 2007 Dec 22;370(9605):2103-11 [18156031.001]
  • [Cites] N Engl J Med. 2007 Dec 27;357(26):2666-76 [18160686.001]
  • [Cites] N Engl J Med. 2008 Mar 13;358(11):1129-36 [18337603.001]
  • [Cites] J Clin Oncol. 2008 Aug 1;26(22):3709-14 [18669456.001]
  • [Cites] J Clin Oncol. 2008 Nov 20;26(33):5422-8 [18936475.001]
  • [Cites] Nephrol Dial Transplant. 2009 Feb;24(2):682-5 [19054798.001]
  • [Cites] J Clin Oncol. 2001 Feb 1;19(3):843-50 [11157038.001]
  • (PMID = 19773375.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA062502-06; United States / NCI NIH HHS / CA / U01 CA062502; United States / NCI NIH HHS / CA / U01 CA062502-06; United States / NCI NIH HHS / CA / U01CA062502
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Indoles; 0 / Pyrroles; 0 / sunitinib; 2S9ZZM9Q9V / Bevacizumab
  • [Other-IDs] NLM/ NIHMS140327; NLM/ PMC2756318
  •  go-up   go-down


36. Karahan N, Güney M, Oral B, Kapucuoglu N, Mungan T: CD24 expression is a poor prognostic marker in endometrial carcinoma. Eur J Gynaecol Oncol; 2006;27(5):500-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: CD24 is a cell adhesion molecule that has been implicated in metastatic tumor progression of various solid tumors.
  • CD24 is commonly up-regulated in endometrial cancer and this corroborates the importance of CD24 in tumor progression among these cases.
  • [MeSH-major] Antigens, CD24 / metabolism. Biomarkers, Tumor / metabolism. Carcinoma, Endometrioid / metabolism. Carcinoma, Papillary / metabolism. Endometrial Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Staging. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17139987.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antigens, CD24; 0 / Biomarkers, Tumor
  •  go-up   go-down


37. Hamadah I, Binamer Y, Alajlan S, Nassar A, Saleh AJ: Squamous cell carcinoma of the lip after allogeneic hemopoietic stem cell transplantation. Hematol Oncol Stem Cell Ther; 2010;3(2):84-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Secondary malignancies are also among the most serious long-term complications after HSCT including leukemia, lymphomas, and to a lesser extent, solid tumors.
  • The most commonly observed solid tumor is squamous cell carcinoma (SCC).
  • [MeSH-minor] Adult. Graft vs Host Disease / pathology. Graft vs Host Disease / surgery. Humans. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy. Male. Multiple Myeloma / pathology. Multiple Myeloma / therapy. Transplantation, Homologous


38. Pectasides D, Koumpou M, Gaglia A, Pectasides M, Lambadiari V, Lianos E, Papaxoinis G, Economopoulos T: Dermatomyositis associated with breast cancer. Anticancer Res; 2006 May-Jun;26(3B):2329-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Breast carcinoma does not represent the most common solid tumor associated with this autoimmune disorder.
  • [MeSH-minor] Adult. Female. Humans. Middle Aged


39. Bonanno G, Iudicone P, Mariotti A, Procoli A, Pandolfi A, Fioravanti D, Corallo M, Perillo A, Scambia G, Pierelli L, Rutella S: Thymoglobulin, interferon-γ and interleukin-2 efficiently expand cytokine-induced killer (CIK) cells in clinical-grade cultures. J Transl Med; 2010;8:129
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Peripheral blood mononuclear cells (PBMC) from 10 healthy donors and 4 patients with solid cancer were primed with IFN-γ on day 0 and low (50 ng/ml), intermediate (250 ng/ml) and high (500 ng/ml) concentrations of either αCD3 mAb or TG on day 1, and were fed with IL-2 every 3 days for 21 days.
  • We also quantified the frequency of bona fide regulatory T cells (Treg), a T-cell subset implicated in the down-regulation of anti-tumor immunity, and tested the in vitro cytotoxic activity of CIK cells against NK-sensitive, chronic myeloid leukaemia K562 cells.
  • CONCLUSIONS: TG fosters the generation of functional CIK cells with no concomitant expansion of tumor-suppressive Treg cells.
  • [MeSH-minor] Adult. Animals. CD8-Positive T-Lymphocytes / cytology. CD8-Positive T-Lymphocytes / drug effects. Cell Proliferation / drug effects. Cells, Cultured. Cytotoxicity, Immunologic / drug effects. Female. Humans. Killer Cells, Natural / cytology. Killer Cells, Natural / drug effects. Middle Aged. Neoplasms / immunology. Phenotype. Rabbits. T-Lymphocytes, Regulatory / cytology. T-Lymphocytes, Regulatory / drug effects. Tissue Donors. Young Adult

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Transl Med. 2010;8:114 [21062439.001]
  • [Cites] J Biomed Biotechnol. 2010;2010:435745 [20368995.001]
  • [Cites] J Immunol. 2001 Feb 15;166(4):2487-94 [11160309.001]
  • [Cites] J Immunol. 2001 Sep 15;167(6):3129-38 [11544298.001]
  • [Cites] Biol Blood Marrow Transplant. 2001;7(10):532-42 [11760085.001]
  • [Cites] Exp Hematol. 2001 Dec;29(12):1503-16 [11750110.001]
  • [Cites] J Immunol Methods. 2002 Jul 1;265(1-2):81-96 [12072180.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2562-71 [12239170.001]
  • [Cites] J Immunol. 2003 Sep 15;171(6):2977-88 [12960322.001]
  • [Cites] Immunity. 2003 Nov;19(5):641-4 [14614851.001]
  • [Cites] Cancer Biol Ther. 2003 Nov-Dec;2(6):610-6 [14688463.001]
  • [Cites] EMBO J. 2004 Jan 28;23(2):255-9 [14685277.001]
  • [Cites] Blood. 2004 Apr 15;103(8):3065-72 [15070686.001]
  • [Cites] Immunol Res. 2004;30(1):29-34 [15258309.001]
  • [Cites] Nat Rev Immunol. 2004 Sep;4(9):665-74 [15343366.001]
  • [Cites] J Exp Med. 1982 Jun 1;155(6):1823-41 [6176669.001]
  • [Cites] J Exp Med. 1986 Sep 1;164(3):814-25 [3489062.001]
  • [Cites] Br J Haematol. 1990 Aug;75(4):578-84 [2207010.001]
  • [Cites] J Exp Med. 1991 Jul 1;174(1):139-49 [1711560.001]
  • [Cites] J Exp Med. 1992 Nov 1;176(5):1387-98 [1357073.001]
  • [Cites] J Immunol. 1994 Aug 15;153(4):1687-96 [7519209.001]
  • [Cites] Blood. 1995 Nov 1;86(9):3493-9 [7579455.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Oct 29;93(22):12433-8 [8901599.001]
  • [Cites] J Exp Med. 1998 Jun 15;187(12):2065-72 [9625766.001]
  • [Cites] Blood. 1998 Nov 1;92(9):3318-27 [9787169.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Oct 12;96(21):12044-9 [10518573.001]
  • [Cites] Eur J Immunol. 2004 Dec;34(12):3413-22 [15549734.001]
  • [Cites] Mol Immunol. 2005 Feb;42(4):485-8 [15607803.001]
  • [Cites] Biol Blood Marrow Transplant. 2005 Mar;11(3):181-7 [15744236.001]
  • [Cites] Blood. 2006 Mar 15;107(6):2409-14 [16304057.001]
  • [Cites] Blood. 2006 Jul 1;108(1):218-27 [16527888.001]
  • [Cites] Blood. 2006 Aug 1;108(3):804-11 [16861339.001]
  • [Cites] Haematologica. 2007 Jul;92(7):952-9 [17606446.001]
  • [Cites] Cancer Res. 2007 Aug 1;67(15):7487-94 [17671219.001]
  • [Cites] J Immunol Methods. 2007 Aug 31;325(1-2):51-66 [17617419.001]
  • [Cites] Nat Rev Immunol. 2007 Sep;7(9):737-44 [17673918.001]
  • [Cites] Transpl Immunol. 2007 Nov;18(2):85-7 [18005849.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 May 6;105(18):6696-701 [18448674.001]
  • [Cites] Immunobiology. 2008;213(8):629-40 [18765168.001]
  • [Cites] Transplantation. 2008 Nov 27;86(10):1419-26 [19034013.001]
  • [Cites] Int Immunopharmacol. 2009 Mar;9(3):375-80 [19105981.001]
  • [Cites] Transplantation. 2009 Feb 27;87(4):473-81 [19307782.001]
  • [Cites] Exp Hematol. 2009 May;37(5):616-628.e2 [19375652.001]
  • [Cites] Drugs. 2009 Jul 30;69(11):1483-512 [19634926.001]
  • [Cites] BMC Immunol. 2009;10:46 [19712464.001]
  • [Cites] Exp Hematol. 2009 Oct;37(10):1216-29 [19638292.001]
  • [Cites] Hematol Oncol. 2009 Sep;27(3):130-9 [19294626.001]
  • [Cites] Blood. 2009 Oct 15;114(16):3422-30 [19628706.001]
  • [Cites] J Cancer Res Clin Oncol. 2011 Feb;137(2):305-10 [20407789.001]
  • (PMID = 21138560.001).
  • [ISSN] 1479-5876
  • [Journal-full-title] Journal of translational medicine
  • [ISO-abbreviation] J Transl Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antilymphocyte Serum; 0 / Interleukin-2; 0 / thymoglobulin; 82115-62-6 / Interferon-gamma
  • [Other-IDs] NLM/ PMC3004824
  •  go-up   go-down


40. Choi HJ, Lee JH, Seo SS, Lee S, Kim SK, Kim JY, Lee JS, Park SY, Kim YH: Computed tomography findings of ovarian metastases from colon cancer: comparison with primary malignant ovarian tumors. J Comput Assist Tomogr; 2005 Jan-Feb;29(1):69-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The CT findings (laterality, size, margin, shape, mass characteristic, strong enhancement of cyst wall, enhancement of solid portion, amount of ascites, peritoneal seeding, lymph node enlargement, and metastasis) and ages of the patients in both groups were compared.
  • RESULTS: A smooth margin of the tumor (odds ratio=24.3, 95% confidence interval: 2.9-204.2) and cystic nature of the mass (Pearson chi=12.96, P=0.005) were strong predictors of ovarian metastasis from colon cancer.
  • [MeSH-minor] Adenocarcinoma, Mucinous / radiography. Adult. Aged. Aged, 80 and over. Ascites / radiography. Contrast Media. Cystadenocarcinoma, Serous / radiography. Female. Humans. Image Processing, Computer-Assisted. Lymph Nodes / radiography. Middle Aged. Myometrium / radiography. Neoplasm Seeding. Peritoneal Neoplasms / secondary. Radiographic Image Enhancement

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15665686.001).
  • [ISSN] 0363-8715
  • [Journal-full-title] Journal of computer assisted tomography
  • [ISO-abbreviation] J Comput Assist Tomogr
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 4419T9MX03 / Iohexol; 712BAC33MZ / iopromide
  •  go-up   go-down


41. Olioso P, Giancola R, Di Riti M, Contento A, Accorsi P, Iacone A: Immunotherapy with cytokine induced killer cells in solid and hematopoietic tumours: a pilot clinical trial. Hematol Oncol; 2009 Sep;27(3):130-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunotherapy with cytokine induced killer cells in solid and hematopoietic tumours: a pilot clinical trial.
  • We started a pilot clinical trial with autologous CIK cells in patients with refractory lymphoma and metastatic solid tumours.
  • [MeSH-minor] Adult. Aged. Blood Transfusion, Autologous. Cell Line, Tumor. Cytokines / blood. Female. Humans. Immunotherapy. Lymphocytes / cytology. Lymphocytes / immunology. Male. Middle Aged. Pilot Projects

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19294626.001).
  • [ISSN] 1099-1069
  • [Journal-full-title] Hematological oncology
  • [ISO-abbreviation] Hematol Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cytokines
  •  go-up   go-down


42. Sundararajan S, Tohno E, Kamma H, Ueno E, Minami M: Detection of intraductal component around invasive breast cancer using ultrasound: correlation with MRI and histopathological findings. Radiat Med; 2006 Feb;24(2):108-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: In 47 patients with invasive breast cancer, US features of the intraductal component were classified as (a) solid ductal dilatation radiating from the tumor, (b) presence of satellite lesion in the same segment without ductal dilatation, and (c) ductal dilatation between the main tumor and satellite lesion.
  • Other criteria for the detection of the intraductal component by MRI were as follows: (a) a satellite lesion around the main tumor, (b) bridging enhancement between the main tumor and satellite lesions.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Contrast Media. Female. Gadolinium DTPA. Humans. Magnetic Resonance Imaging. Middle Aged. Neoplasm Invasiveness. Predictive Value of Tests. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16715671.001).
  • [ISSN] 0288-2043
  • [Journal-full-title] Radiation medicine
  • [ISO-abbreviation] Radiat Med
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Contrast Media; K2I13DR72L / Gadolinium DTPA
  •  go-up   go-down


43. Fritzsche FR, Kristiansen G, Frauenfelder T, Opitz I, Bode P, Moch H, Montani M: Large mixed germ cell tumor in a young patient presenting as an intrapulmonary mass. Pathol Res Pract; 2009;205(8):572-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large mixed germ cell tumor in a young patient presenting as an intrapulmonary mass.
  • The chest X-ray revealed a massive organ-displacing tumor in the right chest not delineable from the mediastinum.
  • The subsequent needle core biopsy was diagnostic for a mixed germ cell tumor comprising immature teratoma and seminoma.
  • After an initially good response to chemotherapy, tumor markers and tumor size were progressive.
  • The right-sided pneumonectomy revealed an intrapulmonary tumor with cystic and solid components, hemorrhage, and necrosis with a tumor diameter of 18cm.
  • Histology confirmed a teratoma with mature and immature components accompanied by residual seminomatous tumor cells.
  • We describe this exceptional large intrapulmonary germ cell tumor and discuss the spectrum of such rare tumors.
  • [MeSH-minor] Adult. Biomarkers, Tumor / metabolism. Combined Modality Therapy. Disease Progression. Fatal Outcome. Humans. Male. Radiography, Thoracic. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Zurich Open Access Repository and Archive. Full text from .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19201104.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


44. Oliva E, Alvarez T, Young RH: Sertoli cell tumors of the ovary: a clinicopathologic and immunohistochemical study of 54 cases. Am J Surg Pathol; 2005 Feb;29(2):143-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • They were all unilateral, usually solid, and often yellow.
  • The tubules were solid or hollow with the former being somewhat more common.
  • Delicate septa were occasionally seen and were conspicuous in areas of one tumor.
  • The cells usually had pale to occasionally densely eosinophilic cytoplasm, but 6 tumors were composed of cells with prominent foamy cytoplasm, falling in the category of "lipid-rich" Sertoli cell tumor, and one had cells with clear non-foamy cytoplasm.
  • Two of the three clinically malignant stage I tumors had moderate to severe cytologic atypia and brisk mitotic activity (>5 or more mitoses/10 high power fields [HPFs]), and one of these had tumor cell necrosis.
  • Among the 10 clinically benign stage I tumors with more than 5 years of follow-up, only 3 had >5 mitoses/10 HPFs, but none had more than mild cytologic atypia and none had tumor cell necrosis.
  • EMA, inhibin, and chromogranin represent the most helpful triad of immunomarkers serving to exclude two common mimics of Sertoli cell tumors (endometrioid carcinoma [inhibin-; EMA+; chromogranin-] and carcinoid tumor [inhibin-; EMA+; chromogranin+]).
  • [MeSH-major] Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology. Sertoli Cell Tumor / metabolism. Sertoli Cell Tumor / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / analysis. Child. Child, Preschool. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Middle Aged. Prognosis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15644771.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


45. Cantisán S, Torre-Cisneros J, Lara R, Rodríguez-Benot A, Santos F, Gutiérrez-Aroca J, Gayoso I, González-Padilla M, Casal M, Rivero A, Solana R: Age-dependent association between low frequency of CD27/CD28 expression on pp65 CD8+ T cells and cytomegalovirus replication after transplantation. Clin Vaccine Immunol; 2009 Oct;16(10):1429-38
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this cross-sectional study of 42 solid organ transplant recipients, the association of human cytomegalovirus (HCMV) replication and age with the phenotype of the HCMV-specific CD8(+) T cells was analyzed by using the CMV pp65 HLA-A*0201 pentamer.
  • These results suggest that the increased percentage of CD27(-) or CD28(-) HCMV-specific subsets can be considered a biomarker of HCMV replication in solid organ transplant recipients younger than age 50 years but not in older patients.
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Antigens, CD27 / metabolism. Antigens, CD28 / metabolism. Cross-Sectional Studies. Cytomegalovirus Infections / immunology. Cytomegalovirus Infections / prevention & control. Cytomegalovirus Infections / transmission. Cytomegalovirus Infections / virology. Female. Granzymes / biosynthesis. Humans. Kidney Transplantation / adverse effects. Kidney Transplantation / immunology. Lung Transplantation / adverse effects. Lung Transplantation / immunology. Male. Middle Aged. Perforin / biosynthesis. T-Lymphocyte Subsets / immunology. T-Lymphocyte Subsets / metabolism. Virus Replication / immunology. Young Adult

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] PLoS Biol. 2004 Feb;2(2):E20 [14966528.001]
  • [Cites] Transpl Int. 2008 Jul;21(7):661-8 [18346013.001]
  • [Cites] J Infect Dis. 2004 May 1;189(9):1619-27 [15116298.001]
  • [Cites] Hum Immunol. 2004 May;65(5):456-64 [15172445.001]
  • [Cites] Hum Immunol. 2004 May;65(5):500-6 [15172450.001]
  • [Cites] Ann N Y Acad Sci. 2004 Jun;1019:123-6 [15247004.001]
  • [Cites] Cancer Immunol Immunother. 2004 Oct;53(10):911-24 [15127235.001]
  • [Cites] Virology. 2005 Feb 5;332(1):16-9 [15661136.001]
  • [Cites] Transplantation. 2005 Feb 27;79(4):381-6 [15729162.001]
  • [Cites] J Virol. 2005 Mar;79(6):3675-83 [15731261.001]
  • [Cites] Immunol Rev. 2005 Jun;205:158-69 [15882352.001]
  • [Cites] Int Immunol. 2009 Jan;21(1):53-62 [19050104.001]
  • [Cites] Curr Top Microbiol Immunol. 2008;325:85-100 [18637501.001]
  • [Cites] Lancet. 2000 Jun 10;355(9220):2032-6 [10885354.001]
  • [Cites] J Exp Med. 2000 Jul 3;192(1):63-75 [10880527.001]
  • [Cites] Blood. 2000 Nov 1;96(9):3094-101 [11049989.001]
  • [Cites] Clin Immunol. 2001 May;99(2):211-221 [11318593.001]
  • [Cites] Blood. 2001 Jul 1;98(1):156-64 [11418475.001]
  • [Cites] Blood. 2001 Aug 1;98(3):754-61 [11468176.001]
  • [Cites] Arthritis Res. 2002;4(1):71-6 [11879540.001]
  • [Cites] Nat Med. 2002 Apr;8(4):379-85 [11927944.001]
  • [Cites] J Immunol. 2002 Aug 15;169(4):1984-92 [12165524.001]
  • [Cites] J Am Soc Nephrol. 2002 Oct;13(10):2577-84 [12239248.001]
  • [Cites] AIDS. 2002 Oct 18;16(15):2001-11 [12370498.001]
  • [Cites] Blood. 2002 Nov 15;100(10):3698-702 [12393723.001]
  • [Cites] Trends Immunol. 2002 Dec;23(12):580-5 [12464569.001]
  • [Cites] Clin Immunol. 2002 Nov;105(2):117-25 [12482386.001]
  • [Cites] Blood. 2003 Apr 1;101(7):2686-92 [12411292.001]
  • [Cites] Blood. 2003 Sep 1;102(5):1779-87 [12750165.001]
  • [Cites] Nat Rev Immunol. 2003 Dec;3(12):931-9 [14647475.001]
  • [Cites] Eur J Immunol. 2004 Apr;34(4):999-1010 [15048710.001]
  • [Cites] Immunol Rev. 2005 Jun;205:257-68 [15882359.001]
  • [Cites] J Gerontol A Biol Sci Med Sci. 2005 May;60(5):556-65 [15972602.001]
  • [Cites] Curr Opin Immunol. 2005 Oct;17(5):480-5 [16098721.001]
  • [Cites] Cancer Immunol Immunother. 2005 Dec;54(12):1162-71 [15889254.001]
  • [Cites] Mech Ageing Dev. 2006 Jun;127(6):538-43 [16513159.001]
  • [Cites] J Virol. 2006 Nov;80(22):11398-403 [16956940.001]
  • [Cites] J Infect Dis. 2006 Dec 1;194(11):1537-46 [17083038.001]
  • [Cites] Hum Immunol. 2007 Feb;68(2):86-90 [17321897.001]
  • [Cites] J Immunol. 2007 Apr 1;178(7):4112-9 [17371966.001]
  • [Cites] Clin Transplant. 2007 Mar-Apr;21(2):149-58 [17425738.001]
  • [Cites] Curr Opin Immunol. 2007 Aug;19(4):408-15 [17656078.001]
  • [Cites] J Virol. 2007 Oct;81(20):11538-42 [17686874.001]
  • [Cites] Ann N Y Acad Sci. 2007 Oct;1114:23-35 [17986574.001]
  • [Cites] Transpl Immunol. 2007 Nov;18(2):186-92 [18005866.001]
  • [Cites] Enferm Infecc Microbiol Clin. 2008 Jan;26(1):38-47 [18208765.001]
  • [Cites] J Clin Virol. 2008 Mar;41(3):213-7 [18061537.001]
  • [Cites] EMBO Rep. 2008 Mar;9(3):234-8 [18259218.001]
  • [Cites] Med Microbiol Immunol. 2008 Jun;197(2):83-96 [18301918.001]
  • [Cites] Am J Transplant. 2008 May;8(5):990-9 [18325078.001]
  • [Cites] J Transl Med. 2008;6:29 [18541023.001]
  • [Cites] Trends Mol Med. 2004 Mar;10(3):119-24 [15102354.001]
  • (PMID = 19656991.001).
  • [ISSN] 1556-679X
  • [Journal-full-title] Clinical and vaccine immunology : CVI
  • [ISO-abbreviation] Clin. Vaccine Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD27; 0 / Antigens, CD28; 0 / Phosphoproteins; 0 / Viral Matrix Proteins; 0 / cytomegalovirus matrix protein 65kDa; 126465-35-8 / Perforin; EC 3.4.21.- / Granzymes
  • [Other-IDs] NLM/ PMC2756845
  •  go-up   go-down


46. Wang Z, Ma QY, Liu QG, Yao YM: [Clinical analysis of 9 cases of solid-cystic pseudopapillary tumor of the pancreas with literature review]. Ai Zheng; 2006 Oct;25(10):1287-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of 9 cases of solid-cystic pseudopapillary tumor of the pancreas with literature review].
  • BACKGROUND & OBJECTIVE: Solid-cystic pseudopapillary tumor of the pancreas (SCPT) is a rare type of pancreatic tumor with low grade of malignancy.
  • Most patients received local resection of the tumor.
  • [MeSH-minor] Adolescent. Adult. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Pancreas / pathology. Pancreatectomy. Pancreatic Cyst / diagnosis. Pancreatic Cyst / pathology. Prognosis. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17059778.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] China
  • [Number-of-references] 15
  •  go-up   go-down


47. Omlie JE, Koutlas IG: Acinic cell carcinoma of minor salivary glands: a clinicopathologic study of 21 cases. J Oral Maxillofac Surg; 2010 Sep;68(9):2053-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Acinic cell carcinoma (ACC) is an infrequent type of malignant salivary gland tumor.
  • Histologically, different patterns that included microcystic, papillary cystic, follicular and solid, and combinations of these types characterized the lesions.
  • After properly diagnosed and treated, this patient has been free of tumor for 4 years.
  • [MeSH-minor] Adolescent. Adult. Aged. Carcinoma, Renal Cell / parasitology. Female. Humans. Kidney Neoplasms / pathology. Lymph Nodes / pathology. Lymphoma / pathology. Male. Middle Aged. Young Adult

  • Genetic Alliance. consumer health - Acinic Cell Carcinoma.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 American Association of Oral and Maxillofacial Surgeons. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20576339.001).
  • [ISSN] 1531-5053
  • [Journal-full-title] Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons
  • [ISO-abbreviation] J. Oral Maxillofac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. O'Connor JP, Jayson GC, Jackson A, Ghiorghiu D, Carrington BM, Rose CJ, Mills SJ, Swindell R, Roberts C, Mitchell CL, Parker GJ: Enhancing fraction predicts clinical outcome following first-line chemotherapy in patients with epithelial ovarian carcinoma. Clin Cancer Res; 2007 Oct 15;13(20):6130-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The proportion of enhancing tumor tissue--the enhancing fraction--was calculated on pre-chemotherapy computed tomography scans at four Hounsfield unit (HU) thresholds and assessed for correlation with CA125 response, Response Evaluation Criteria in Solid Tumors (RECIST) radiologic response, and time to progression.
  • RESULTS: Pre-chemotherapy residual tumor volume did not correlate with clinical outcome.
  • Enhancing fraction predicted CA125 response with 81.9% to 86.4% specificity and Response Evaluation Criteria in Solid Tumors response with 74.9% to 76.8% specificity at 95% sensitivity (dependent on threshold).
  • [MeSH-major] Antineoplastic Agents / pharmacology. Biomarkers, Tumor. Carcinoma / genetics. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Angiogenesis Inhibitors / pharmacology. Antineoplastic Combined Chemotherapy Protocols / pharmacology. False Positive Reactions. Female. Humans. Middle Aged. Models, Biological. Prognosis. Sensitivity and Specificity. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17947478.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0601746; United Kingdom / Medical Research Council / / G0902173
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor
  •  go-up   go-down


49. Golshayan AR, George S, Heng DY, Elson P, Wood LS, Mekhail TM, Garcia JA, Aydin H, Zhou M, Bukowski RM, Rini BI: Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. J Clin Oncol; 2009 Jan 10;27(2):235-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: Patients who had mRCC with sarcomatoid features in the primary tumor and who were treated with VEGF-targeted therapy were retrospectively identified.
  • Objective response rate, percentage of tumor burden shrinkage, progression-free survival (PFS), and overall survival (OS) were determined.
  • Median tumor shrinkage was -2% (range, -85% to 127%), and 53% achieved some degree of tumor shrinkage on therapy.
  • CONCLUSION: Patients who have mRCC and sarcomatoid differentiation can demonstrate objective responses and tumor shrinkage to VEGF-targeted therapy.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Benzenesulfonates / therapeutic use. Bevacizumab. Drug Delivery Systems. Female. Humans. Indoles / administration & dosage. Indoles / therapeutic use. Male. Middle Aged. Neoplasm Metastasis. Niacinamide / analogs & derivatives. Phenylurea Compounds. Pyridines / therapeutic use. Pyrroles / administration & dosage. Pyrroles / therapeutic use. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19064974.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Indoles; 0 / Phenylurea Compounds; 0 / Pyridines; 0 / Pyrroles; 0 / Vascular Endothelial Growth Factor A; 0 / sunitinib; 25X51I8RD4 / Niacinamide; 2S9ZZM9Q9V / Bevacizumab; 9ZOQ3TZI87 / sorafenib
  •  go-up   go-down


50. Lönnrot K, Terho M, Kähärä V, Haapasalo H, Helén P: Desmoplastic infantile ganglioglioma: novel aspects in clinical presentation and genetics. Surg Neurol; 2007 Sep;68(3):304-8; discussion 308
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Desmoplastic infantile ganglioglioma is a rare tumor occurring mainly in infants and young children.
  • In 4 cases, there was a histopathologically verified single cystic tumor.
  • There were no recurrences in any of the patients after tumor resection.
  • The radiological appearance of DIG may vary from cystic to solid and from contrast-enhancing to nonenhancing.
  • [MeSH-minor] Adult. Aged. Child. Child, Preschool. Epilepsy / etiology. Follow-Up Studies. Humans. Male. Neoplasm Proteins / metabolism. Nerve Tissue Proteins / metabolism. Oncogenes / physiology. Retrospective Studies. Treatment Outcome


51. Seiz M, Tuettenberg J, Meyer J, Essig M, Schmieder K, Mawrin C, von Deimling A, Hartmann C: Detection of IDH1 mutations in gliomatosis cerebri, but only in tumors with additional solid component: evidence for molecular subtypes. Acta Neuropathol; 2010 Aug;120(2):261-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of IDH1 mutations in gliomatosis cerebri, but only in tumors with additional solid component: evidence for molecular subtypes.
  • We identified IDH1 mutations in 10/24 (42%) cases, which also included a solid tumor portion (type 2 GC), but not in 11 "classical" cases without solid tumor mass (type 1 GC).
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Arginine / genetics. Astrocytoma / secondary. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. DNA Mutational Analysis. Female. Histidine / genetics. Humans. In Situ Hybridization, Fluorescence / methods. Magnetic Resonance Imaging / methods. Male. Middle Aged. Oligodendroglioma / secondary. Polymorphism, Single Nucleotide / genetics. Tumor Suppressor Protein p53 / genetics. Tumor Suppressor Protein p53 / metabolism


52. Erovic BM, Neuchrist C, Berger U, El-Rabadi K, Burian M: Quantitation of microvessel density in squamous cell carcinoma of the head and neck by computer-aided image analysis. Wien Klin Wochenschr; 2005 Jan;117(1-2):53-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, growth, invasion, and metastasis of most solid tumors are dependent on angiogenesis.
  • Therefore, neovascularization is a basic requirement for nutrition and oxygenation of tumor cells.
  • Numerous studies in different solid as well as non-solid tumors have evaluated the prognostic value of tumor neovascularization.
  • In solid tumors the increased microvessel density, the pathological correlate to tumor neovascularization, has been linked to a worse prognosis of the disease.
  • The aim of the current study was to assess the prognostic value of tumor neovascularization for recurrences in squamous cell carcinoma of the head and neck by determining microvessel density.
  • BASIC RESEARCH DESIGN: Immunohistochemistry was performed to detect intratumoral microvessels in tumor samples of 50 patients with squamous cell carcinoma of the head and neck.
  • After immunostaining, the entire tumor section was scanned microscopically at low power (x 40) to identify hot spots, which are the areas of highest neovascularization.
  • Individual tumor microvessels were then counted under high power (x 200) to obtain a vessel count in a defined area, and the average vessel count in 4 hot spots was taken as the microvessel density.
  • However, no further statistical correlations between microvessel density and patients clinical data i.e. tumor status, lymph node status, overall survival, or disease free interval could be found.
  • CONCLUSION: There is mounting evidence that suggests, that assessment of tumor neovascularization might provide a novel approach of prognostication in patients with squamous cell carcinomas of the head and neck.
  • In particular, in the present study, the degree of angiogenesis of a tumor, as assessed by microvessel density, was found to be correlated with recurrent disease in squamous cell carcinoma of the head and neck.
  • Computer aided image analysis, an automated technique, constitutes a time-efficient and reproducible technique for quantification of tumor vascularization.
  • However, for a reliable and reproducible assessment of tumor neovascularization, validation procedures and quality control protocols are mandatory.
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Observer Variation. Reproducibility of Results. Sensitivity and Specificity. Severity of Illness Index

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15986592.001).
  • [ISSN] 0043-5325
  • [Journal-full-title] Wiener klinische Wochenschrift
  • [ISO-abbreviation] Wien. Klin. Wochenschr.
  • [Language] eng
  • [Publication-type] Clinical Trial; Controlled Clinical Trial; Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


53. Oton AB, Wang H, Leleu X, Melhem MF, George D, Lacasce A, Foon K, Ghobrial IM: Clinical and pathological prognostic markers for survival in adult patients with post-transplant lymphoproliferative disorders in solid transplant. Leuk Lymphoma; 2008 Sep;49(9):1738-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and pathological prognostic markers for survival in adult patients with post-transplant lymphoproliferative disorders in solid transplant.
  • We sought to determine the clinical and immunohistopathological prognostic factors for overall survival (OS) in adult patients with post-transplant lymphoproliferative disorders (PTLDs).
  • Immunohistochemical staining was performed on tumor tissue at the time of diagnosis for the following proteins: Bcl-2, Bcl-6, c-myc and p53.
  • [MeSH-minor] Biomarkers / analysis. Prognosis. Proto-Oncogene Proteins c-bcl-2 / analysis. Proto-Oncogene Proteins c-bcl-6 / analysis. Proto-Oncogene Proteins c-myc / analysis. Risk Factors. Survival Analysis. Tumor Suppressor Protein p53 / analysis

  • MedlinePlus Health Information. consumer health - Organ Transplantation.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18798108.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / MYC protein, human; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Proto-Oncogene Proteins c-bcl-6; 0 / Proto-Oncogene Proteins c-myc; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


54. Beaty MW, Quezado M, Sobel ME, Duray P, Merino MJ: Loss of heterozygosity on chromosome 1 and 9 and hormone receptor analysis of metastatic malignant melanoma presenting in breast. Int J Surg Pathol; 2005 Jan;13(1):9-18
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant melanoma (MM), the most common metastatic solid tumor to involve the breast, may present as a diagnostic problem, frequently requiring the use of ancillary studies for accurate diagnosis.
  • Visually directed microdissection was performed on archival histologic slides containing both tumor and adjacent normal breast epithelium, followed by single-step DNA extraction and polymerase chain reaction (PCR) amplification for evaluation of loss of heterozygosity (LOH) for the above-listed markers.
  • Five cases were heterozygous for D9S12, and 2 (40%) showed LOH in the tumor at 9q22.3.
  • Metastatic MM presenting as a breast mass is an interesting entity often requiring IHC studies for diagnosis, particularly when the histologic features simulate breast carcinoma or when no primary tumor is known.
  • [MeSH-minor] Adult. Biomarkers, Tumor. DNA, Neoplasm / analysis. Female. Humans. Immunoenzyme Techniques. Male. Microdissection. Middle Aged. Polymerase Chain Reaction. Receptors, Estrogen / analysis. Receptors, Progesterone / analysis

  • Genetic Alliance. consumer health - Chromosome 9.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15735850.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone
  •  go-up   go-down


55. Zhang Y, Li H: Primitive neuroectodermal tumors of adrenal gland. Jpn J Clin Oncol; 2010 Aug;40(8):800-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The masses were 8-17 cm in diameter with solid-cystic changes.
  • CONCLUSIONS: Adrenal primitive neuroectodermal tumor is a very rare tumor.
  • The tumor is fast-developing, highly malignant with poor prognosis.
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Fatal Outcome. Female. Follow-Up Studies. Humans. Laparotomy. Lymphatic Metastasis. Male. Neoplastic Cells, Circulating / pathology. Neoplastic Cells, Circulating / ultrastructure. Radiographic Image Enhancement. Retrospective Studies. Tomography, X-Ray Computed. Vena Cava, Inferior / radiography

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20430773.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


56. Aslanian H, Salem R, Lee J, Andersen D, Robert M, Topazian M: EUS diagnosis of vascular invasion in pancreatic cancer: surgical and histologic correlates. Am J Gastroenterol; 2005 Jun;100(6):1381-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: All patients with solid pancreatic masses who underwent both preoperative EUS and surgery at 1 hospital over a 7 year period were identified.
  • "Vascular adherence" was defined as tumor adherence requiring vascular resection during surgery, and "vascular invasion" as histologic invasion of vessel wall by tumor.
  • Among these 30, vascular adherence was present in 8, including 18% of patients with an intact echoplane between tumor and adjacent vessels at EUS, 29% of those with loss of echoplane alone, and 50% of those with additional EUS features of vascular involvement.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Celiac Artery / pathology. Celiac Artery / ultrasonography. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Male. Mesenteric Veins / pathology. Mesenteric Veins / ultrasonography. Middle Aged. Monitoring, Intraoperative / methods. Neoplasm Invasiveness. Neoplasm Staging. Palpation. Portal Vein / parasitology. Portal Vein / ultrasonography. Predictive Value of Tests. Retrospective Studies. Sensitivity and Specificity. Vena Cava, Inferior / pathology. Vena Cava, Inferior / ultrasonography. Videotape Recording

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15929774.001).
  • [ISSN] 0002-9270
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Chong YP, Choi SH, Kim ES, Song EH, Lee EJ, Park KH, Cho OH, Kim SH, Lee SO, Kim MN, Jeong JY, Woo JH, Kim YS: Bloodstream infections caused by qnr-positive Enterobacteriaceae: clinical and microbiologic characteristics and outcomes. Diagn Microbiol Infect Dis; 2010 May;67(1):70-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A comparison of these 26 qnr-positive and 297 qnr-negative Enterobacteriaceae BSIs in adult patients showed that the population characteristics and clinical features of BSIs were similar between the qnr-positive and qnr-negative groups.
  • However, patients with hematologic malignancies, solid organ transplant recipients, and BSIs caused by strains with multiple antimicrobial resistance, including extended-spectrum beta-lactamase (ESBL) resistance, were more common in the qnr-positive group.
  • In the multivariate analysis, prior use of trimethoprim-sulfamethoxazole (odds ratio [OR], 5.55; 95% confidence interval [CI], 1.47-20.94) and having an underlying disease other than solid tumor (OR, 4.06; 95% CI, 15.07) were independently associated with qnr-positive Enterobacteriaceae BSIs.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Anti-Bacterial Agents / pharmacology. DNA, Bacterial / chemistry. DNA, Bacterial / genetics. Female. Humans. Male. Middle Aged. Plasmids. Polymerase Chain Reaction. Prospective Studies. Sequence Analysis, DNA. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Antibiotic Resistance.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20227228.001).
  • [ISSN] 1879-0070
  • [Journal-full-title] Diagnostic microbiology and infectious disease
  • [ISO-abbreviation] Diagn. Microbiol. Infect. Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Bacterial Proteins; 0 / DNA, Bacterial; 0 / Quinolones
  •  go-up   go-down


58. Matushansky I, Hernando E, Socci ND, Matos T, Mills J, Edgar MA, Schwartz GK, Singer S, Cordon-Cardo C, Maki RG: A developmental model of sarcomagenesis defines a differentiation-based classification for liposarcomas. Am J Pathol; 2008 Apr;172(4):1069-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The importance of adult stem cells in the development of neoplastic diseases is becoming increasingly well appreciated.
  • Our results indicate that a degree of developmental maturity can be quantitatively assigned to solid tumors, supporting the notion that transformation of a solid tumor stem cell can occur at distinct stages of maturation.

  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 1989 Sep;20(9):914-7 [2673981.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Oct 19;101(42):15184-9 [15477599.001]
  • [Cites] Cancer Chemother Pharmacol. 1994;34(1):79-80 [8174207.001]
  • [Cites] Ann Surg Oncol. 1997 Oct-Nov;4(7):557-63 [9367021.001]
  • [Cites] J Biol Chem. 1998 Jun 19;273(25):15574-81 [9624148.001]
  • [Cites] J Pathol. 1998 Jun;185(2):188-90 [9713346.001]
  • [Cites] Magn Reson Med. 1999 Feb;41(2):257-67 [10080272.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3951-6 [10097144.001]
  • [Cites] Clin Chem. 1999 Oct;45(10):1708-17 [10508115.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Nov;155(1):1-24 [15527898.001]
  • [Cites] Nat Rev Cancer. 2005 Aug;5(8):649-55 [16056260.001]
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9226-35 [16230383.001]
  • [Cites] Biochim Biophys Acta. 2005 Nov 25;1756(2):81-2 [16269215.001]
  • [Cites] Cancer Cell. 2007 Apr;11(4):375-88 [17418413.001]
  • [Cites] Cancer Res. 2007 Jul 15;67(14):6626-36 [17638873.001]
  • [Cites] J Clin Invest. 2007 Nov;117(11):3248-57 [17948129.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3213-8 [10725391.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21 [11309499.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10398-403 [11526243.001]
  • [Cites] J Am Chem Soc. 2001 Sep 19;123(37):9200-1 [11552844.001]
  • [Cites] Lancet. 2002 Apr 13;359(9314):1301-7 [11965276.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Jun;88(6):2412-21 [12788836.001]
  • [Cites] Am J Pathol. 2003 Aug;163(2):691-700 [12875988.001]
  • [Cites] Br J Cancer. 2003 Oct 20;89(8):1409-12 [14562008.001]
  • [Cites] J Bone Miner Res. 2004 Feb;19(2):256-64 [14969395.001]
  • [Cites] Mol Cell Biol. 1994 Mar;14(3):2066-76 [8114738.001]
  • (PMID = 18310505.001).
  • [ISSN] 0002-9440
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA047179; United States / NCI NIH HHS / CA / CA 47179
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins
  • [Other-IDs] NLM/ PMC2276417
  •  go-up   go-down


59. Qiu MZ, Yuan ZY, Luo HY, Ruan DY, Wang ZQ, Wang FH, Li YH, Xu RH: Impact of pretreatment hematologic profile on survival of colorectal cancer patients. Tumour Biol; 2010 Aug;31(4):255-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pretreatment hematologic abnormalities have been reported to have prognostic value in patients with solid tumors.
  • Univariate analysis showed that advanced tumor stages, leukocytosis, anemia, thrombocytosis, and low histological grade were all significantly associated with shorter survival.
  • The multivariate Cox analysis revealed that low histological grade, tumor stage, pretreatment anemia, and thrombocytosis remained independent prognostic variables for survival.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Platelet Count. Prognosis. Retrospective Studies. Survival Rate. Young Adult

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Anemia.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Tex Med. 1990 Oct;86(10):80-3 [2247849.001]
  • [Cites] Clin Otolaryngol. 2008 Jun;33(3):245-51 [18559031.001]
  • [Cites] Cancer. 2001 Jun 15;91(12):2214-21 [11413508.001]
  • [Cites] Thromb Haemost. 2003 Jun;89(6):1098-106 [12783124.001]
  • [Cites] Eur Respir J. 1996 Sep;9(9):1826-30 [8880098.001]
  • [Cites] Thromb Haemost. 1998 May;79(5):916-8 [9609220.001]
  • [Cites] Ann Oncol. 2005 Jun;16(6):988-9 [15879160.001]
  • [Cites] Oncology. 2000 Feb;58(2):169-74 [10705245.001]
  • [Cites] Cancer. 2001 Nov 1;92(9):2399-405 [11745296.001]
  • [Cites] Cancer. 2005 Apr 15;103(8):1740-6 [15742330.001]
  • [Cites] Semin Oncol. 1998 Jun;25(3 Suppl 7):2-6 [9671322.001]
  • [Cites] Urology. 2004 Mar;63(3):447-50 [15028435.001]
  • [Cites] Thromb Haemost. 1990 Dec 28;64(4):501-5 [1964750.001]
  • [Cites] Tumour Biol. 2000 Sep-Oct;21(5):309-14 [10940827.001]
  • [Cites] Gynecol Oncol. 2004 Jan;92(1):211-4 [14751160.001]
  • [Cites] J Am Coll Surg. 2004 May;198(5):737-41 [15110807.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jul 1;56(3):778-87 [12788185.001]
  • [Cites] J Cancer Res Clin Oncol. 2009 Dec;135(12):1783-90 [19551407.001]
  • [Cites] Clin Chim Acta. 2007 May 1;380(1-2):208-12 [17368603.001]
  • [Cites] JAMA. 1982 Feb 19;247(7):1004-6 [7035703.001]
  • [Cites] Ann Surg Oncol. 2002 Apr;9(3):287-91 [11923136.001]
  • [Cites] J Cell Mol Med. 2009 Mar;13(3):555-61 [18429933.001]
  • [Cites] J Clin Epidemiol. 1996 Dec;49(12):1373-9 [8970487.001]
  • [Cites] Oral Oncol. 2007 Mar;43(3):283-8 [16920387.001]
  • [Cites] Neuro Oncol. 2007 Jul;9(3):335-42 [17504931.001]
  • [Cites] Hepatogastroenterology. 2004 May-Jun;51(57):847-53 [15143932.001]
  • [Cites] Nat Cell Biol. 2008 Mar;10 (3):295-305 [18297062.001]
  • (PMID = 20336401.001).
  • [ISSN] 1423-0380
  • [Journal-full-title] Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
  • [ISO-abbreviation] Tumour Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Vargas-Serrano B, Domínguez-Ferreras E, Chinchón-Espino D: Four cases of solid pseudopapillary tumors of pancreas: imaging findings and pathological correlations. Eur J Radiol; 2006 Apr;58(1):132-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Four cases of solid pseudopapillary tumors of pancreas: imaging findings and pathological correlations.
  • OBJECTIVE: Solid pseudopapillary tumor of the pancreas (SPTP tumor) is a rare pancreatic neoplasm with low malignant potential, which usually affects female patients in the second or third decades of life.
  • It is a non-functional, slow-growing neoplasm that very often reaches considerable size before the first symptoms appear.
  • Symptomatology is frequently related to tumor size.
  • Infrequently the tumor can appear in male patients or in aged women, which can make the diagnosis more difficult.
  • RESULTS: Four cases of solid pseudopapillary tumor of the pancreas were diagnosed and treated in our institution in the study period.
  • CONCLUSION: Solid pseudopapillary tumors are well-encapsulated neoplasms that usually have a good prognosis after surgical excision.
  • [MeSH-minor] Adult. Contrast Media / administration & dosage. Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Retrospective Studies. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16377114.001).
  • [ISSN] 0720-048X
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


61. Lieu C, Chow L, Pierson AS, Eckhardt SG, O'Bryant CL, Morrow M, Tran ZV, Wright JJ, Gore L: A phase I study of bortezomib, etoposide and carboplatin in patients with advanced solid tumors refractory to standard therapy. Invest New Drugs; 2009 Feb;27(1):53-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I study of bortezomib, etoposide and carboplatin in patients with advanced solid tumors refractory to standard therapy.
  • PURPOSE: To evaluate the toxicity, pharmacological, and biological properties of the combination of bortezomib, etoposide, and carboplatin in adults with advanced solid malignancies.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2005 Aug 1;11(15):5526-33 [16061869.001]
  • [Cites] Int J Cancer. 2005 Nov 20;117(4):670-82 [15945097.001]
  • [Cites] Clin Adv Hematol Oncol. 2003 Mar;1(3):190 [16235416.001]
  • [Cites] Bull Cancer. 2005 Nov;92(11):E61-6, 945-52 [16316823.001]
  • [Cites] Annu Rev Med. 2006;57:33-47 [16409135.001]
  • [Cites] Clin Cancer Res. 2006 Feb 15;12(4):1270-5 [16489083.001]
  • [Cites] Future Oncol. 2005 Apr;1(2):161-71 [16555986.001]
  • [Cites] Br J Cancer. 2002 Oct 7;87(8):825-33 [12373594.001]
  • [Cites] Curr Opin Oncol. 2002 Nov;14(6):628-34 [12409653.001]
  • [Cites] Semin Urol Oncol. 2002 Nov;20(4):244-50 [12489057.001]
  • [Cites] Blood. 2003 Mar 15;101(6):2377-80 [12424198.001]
  • [Cites] Cancer Treat Rev. 2003 May;29 Suppl 1:21-31 [12738240.001]
  • [Cites] J Clin Oncol. 2004 Jan 1;22(1):115-9 [14701773.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2108-21 [15169797.001]
  • [Cites] Cancer Invest. 2004;22(2):328-9 [15199617.001]
  • [Cites] Ann Med. 2004;36(4):296-303 [15224656.001]
  • [Cites] Curr Med Chem. 2004 Sep;11(18):2443-66 [15379707.001]
  • [Cites] Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6111-8 [15447997.001]
  • [Cites] Radiother Oncol. 1988 May;12(1):31-7 [2841723.001]
  • [Cites] J Clin Oncol. 1989 Nov;7(11):1748-56 [2681557.001]
  • [Cites] Biochem Pharmacol. 1991 Jul 5;42(2):357-63 [1859450.001]
  • [Cites] J Clin Oncol. 1994 Nov;12(11):2471-508 [7964965.001]
  • [Cites] Science. 1995 Apr 28;268(5210):522-3 [7725095.001]
  • [Cites] Immunity. 1995 May;2(5):493-506 [7538441.001]
  • [Cites] Biochem Biophys Res Commun. 1995 Oct 4;215(1):292-301 [7575604.001]
  • [Cites] Clin Cancer Res. 1998 May;4(5):1087-100 [9607565.001]
  • [Cites] Bioorg Med Chem Lett. 1998 Feb 17;8(4):333-8 [9871680.001]
  • [Cites] Clin Cancer Res. 1999 Sep;5(9):2638-45 [10499643.001]
  • [Cites] Oncogene. 2005 Jan 13;24(3):344-54 [15531918.001]
  • [Cites] Cancer. 2005 Apr 1;103(7):1431-8 [15739208.001]
  • [Cites] Anticancer Drugs. 2005 Jun;16(5):475-81 [15846112.001]
  • [Cites] Clin Cancer Res. 2005 May 1;11(9):3410-6 [15867242.001]
  • [Cites] Cancer. 2005 Jun 15;103(12):2584-9 [15887220.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 May 1;50(1):183-93 [11316563.001]
  • [Cites] J Cell Biochem. 2001 Apr 2-27;82(1):110-22 [11400168.001]
  • [Cites] J Surg Res. 2001 Sep;100(1):11-7 [11516199.001]
  • [Cites] Am J Clin Pathol. 2001 Nov;116(5):637-46 [11710679.001]
  • [Cites] Semin Oncol. 2001 Dec;28(6):613-9 [11740819.001]
  • [Cites] Oncologist. 2002;7(1):9-16 [11854543.001]
  • [Cites] Clin Cancer Res. 2002 Aug;8(8):2505-11 [12171876.001]
  • (PMID = 18618082.001).
  • [ISSN] 0167-6997
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA106349-05; United States / NCI NIH HHS / CA / K24 CA106349-05; United States / NCI NIH HHS / CA / CA086913; United States / PHS HHS / / N01-C0-12400; United States / NCI NIH HHS / CA / K24 CA106349; United States / PHS HHS / / 22XS047A-P3358; United States / NCI NIH HHS / CA / K12 CA086913
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Boronic Acids; 0 / Pyrazines; 69G8BD63PP / Bortezomib; 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin
  • [Other-IDs] NLM/ NIHMS169571; NLM/ PMC2829404
  •  go-up   go-down


62. Rodesch G, Gaillard S, Loiseau H, Brotchi J: Embolization of intradural vascular spinal cord tumors : report of five cases and review of the literature. Neuroradiology; 2008 Feb;50(2):145-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The clinical and radiological charts of five patients, each with a large solid VSCT (four cervical hemangiobastomas, one filum terminale paraganglioma), were retrospectively reviewed.
  • RESULTS: Intranidal deposition of the glue was successful in all four patients, resulting in significant devascularization of the tumor.
  • Surgery became possible in each case under improved conditions with minimal blood loss, thereby allowing total (four cases of hemangioblastomas) or subtotal (one case of paraganglioma) removal of the tumor.
  • Despite its solid aspect after deposition, glue does not hinder surgery but facilitates the manipulation and eradication of the tumor.
  • [MeSH-minor] Adult. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 2003 Jan;98(1):82-94 [12546356.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1992 Oct;55(10):898-901 [1431953.001]
  • [Cites] Neurosurgery. 2002 May;50(5):1059-63 [11950409.001]
  • [Cites] Neurol Med Chir (Tokyo). 2001 May;41(5):246-51; discussion 251-2 [11396304.001]
  • [Cites] J Spinal Disord Tech. 2002 Aug;15(4):319-23 [12177549.001]
  • [Cites] J Neurosurg. 1989 Jan;70(1):24-30 [2909683.001]
  • [Cites] AJNR Am J Neuroradiol. 1996 Mar;17 (3):525-31 [8881249.001]
  • [Cites] Neurol India. 2004 Jun;52(2):243-4 [15269482.001]
  • [Cites] J Neurosurg. 2000 Oct;93(2 Suppl):183-93 [11012047.001]
  • [Cites] AJR Am J Roentgenol. 2000 Feb;174(2):377-82 [10658709.001]
  • [Cites] J Neurooncol. 2005 Mar;72(1):49-55 [15803375.001]
  • [Cites] Neurosurgery. 2005 Oct;57(4 Suppl):372-6; discussion 372-6 [16234688.001]
  • [Cites] J Neurooncol. 2003 Jan;61(1):27-34 [12587793.001]
  • [Cites] AJNR Am J Neuroradiol. 1992 Sep-Oct;13(5):1343-52 [1414827.001]
  • [Cites] Neuroradiology. 1997 Feb;39(2):86-9 [9045967.001]
  • [Cites] Neurosurg Clin N Am. 2000 Jan;11(1):167-85, x [10565876.001]
  • [Cites] AJNR Am J Neuroradiol. 2005 Apr;26(4):936-45 [15814949.001]
  • [Cites] J Neurosurg. 2003 Jan;98(1):106-16 [12546358.001]
  • [Cites] Arch Neurol. 1976 Jun;33(6):435-41 [945725.001]
  • [Cites] AJNR Am J Neuroradiol. 1999 Nov-Dec;20(10 ):2009-15 [10588136.001]
  • [Cites] Neurosurg Rev. 1996;19(3):147-51 [8875501.001]
  • [Cites] AJR Am J Roentgenol. 1993 Apr;160(4):851-2 [8456679.001]
  • [Cites] Neurosurgery. 1994 Oct;35(4):671-5; discussion 675-6 [7808610.001]
  • [Cites] Acta Neurochir (Wien). 1999;141(4):333-9; discussion 339-40 [10352742.001]
  • [Cites] Neurochirurgie. 1975 Jun;21 Suppl 1:1-136 [1103000.001]
  • [Cites] Radiology. 1990 Dec;177(3):651-8 [2243964.001]
  • [Cites] Neurochirurgie. 1994;40(3):155-64 [7723922.001]
  • [Cites] Neurosurgery. 1993 Sep;33(3):502-5; discussion 505 [8413884.001]
  • [Cites] Neurosurgery. 2003 Jul;53(1):40-9; discussion 49-50 [12823872.001]
  • [Cites] Neurosurgery. 2003 Dec;53(6):1306-13; discussion 1313-4 [14633297.001]
  • (PMID = 17932665.001).
  • [ISSN] 0028-3940
  • [Journal-full-title] Neuroradiology
  • [ISO-abbreviation] Neuroradiology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 33
  •  go-up   go-down


63. Motzer RJ, Nichols CJ, Margolin KA, Bacik J, Richardson PG, Vogelzang NJ, Bajorin DF, Lara PN Jr, Einhorn L, Mazumdar M, Bosl GJ: Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. J Clin Oncol; 2007 Jan 20;25(3):247-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To investigate the role of high-dose chemotherapy (HDCT) as first-line treatment in patients with metastatic germ cell tumor (GCT) and poor-prognostic clinical features.
  • Serum tumor marker decline during chemotherapy was assessed prospectively as a predictor of treatment outcome.
  • Serum tumor markers alpha-fetoprotein and human chorionic gonadotrophin were correlated with treatment outcome as a secondary end point.
  • Patients with slow serum tumor marker decline (alpha-fetoprotein and/or human chorionic gonadotrophin) during the first two cycles of chemotherapy had a shorter progression-free survival and overall survival compared with patients with satisfactory marker decline (P = .02 and P = .03, respectively).
  • [MeSH-minor] Adolescent. Adult. Biomarkers, Tumor / blood. Bleomycin / administration & dosage. Carboplatin / administration & dosage. Cisplatin / administration & dosage. Disease Progression. Etoposide / administration & dosage. Humans. Male. Middle Aged. Neoplasm Metastasis. Prognosis. Survival Analysis. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2007 Jan 20;25(3):239-40 [17235039.001]
  • (PMID = 17235042.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-05826; United States / NCI NIH HHS / CA / CA-2115; United States / NCI NIH HHS / CA / CA-23318; United States / NCI NIH HHS / CA / CA-49883; United States / NCI NIH HHS / CA / CA-66636
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin; Q20Q21Q62J / Cisplatin; BEP protocol
  •  go-up   go-down


64. Kotru M, Manucha V, Singh UR: Unicystic granulosa cell tumor: a case report. Indian J Pathol Microbiol; 2005 Apr;48(2):238-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unicystic granulosa cell tumor: a case report.
  • They may be solid, cystic or both.
  • [MeSH-major] Granulosa Cell Tumor / pathology. Ovarian Cysts / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Follicular Cyst / pathology. Humans

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cysts.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16758680.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


65. Storck K, Hadi UM, Simpson R, Ramer M, Brandwein-Gensler M: Sinonasal renal cell-like adenocarcinoma: a report on four patients. Head Neck Pathol; 2008 Jun;2(2):75-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: We have described an unusual sinonasal neoplasm which is a histological mimic of renal cell carcinoma (RCC) and coined the nosological classification "sinonasal renal cell-like adenocarcinoma" (SRCLA) to describe this unusual entity.
  • Histologically, these tumors were uniformly composed of clear cells, forming either solid or glandular patterns.
  • The tumor cells were cuboidal to polyhedral; transition to short spindle cells was seen in one case.
  • [MeSH-minor] Adult. Aged. Carcinoma, Renal Cell / diagnosis. Carcinoma, Renal Cell / secondary. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Kidney Neoplasms / pathology. Male. Middle Aged. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Indian J Pathol Microbiol. 2003 Jan;46(1):93-5 [15027741.001]
  • [Cites] Am J Surg Pathol. 2001 Jul;25(7):835-45 [11420454.001]
  • [Cites] Histopathology. 2008 Jan;52(2):158-66 [18036175.001]
  • [Cites] Ear Nose Throat J. 2001 Jul;80(7):462-7 [11480304.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2002 Apr;128(4):441-7 [11926922.001]
  • [Cites] Rhinology. 2002 Mar;40(1):44-7 [12012954.001]
  • [Cites] Ear Nose Throat J. 2002 Aug;81(8):519-22 [12199168.001]
  • [Cites] Am J Otolaryngol. 2004 Jul-Aug;25(4):255-7 [15239032.001]
  • [Cites] Laryngoscope. 1973 Sep;83(9):1527-39 [4758761.001]
  • [Cites] Mt Sinai J Med. 1988 Oct;55(5):417-20 [3265187.001]
  • [Cites] Urol Int. 2004;73(3):285-6 [15539854.001]
  • [Cites] Oral Oncol. 2005 Jan;41(1):3-10 [15598579.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2005 Jan;262(1):69-71 [14986018.001]
  • [Cites] Surg Today. 2005;35(4):300-3 [15815846.001]
  • [Cites] Laryngoscope. 2005 Jun;115(6):1097-100 [15933529.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2005 Dec;13(4):347-52 [16280664.001]
  • [Cites] Acta Cytol. 2005 Sep-Oct;49(5):543-8 [16334034.001]
  • [Cites] Urology. 2006 Jan;67(1):199 [16413368.001]
  • [Cites] Oral Dis. 2006 Jul;12(4):364-70 [16792720.001]
  • [Cites] Otolaryngol Head Neck Surg. 2000 Mar;122(3):464 [10699832.001]
  • (PMID = 20614326.001).
  • [ISSN] 1936-0568
  • [Journal-full-title] Head and neck pathology
  • [ISO-abbreviation] Head Neck Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2807555
  • [Keywords] NOTNLM ; Renal cell carcinoma / Renal cell-like carcinoma / Sinonasal / Vermeer
  •  go-up   go-down


66. Cui M, Yu W, Dong J, Chen J, Zhang X, Liu Y: Downregulation of ABI1 expression affects the progression and prognosis of human gastric carcinoma. Med Oncol; 2010 Sep;27(3):632-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Abelson interactor protein-1 (ABI1) is a promising candidate tumor suppressor, and plays critical roles both in the pathogenesis of BCR-Abl-induced leukemia and in the spread of several solid tumors.
  • The expression of ABI1 and its role in cancer progression and prognosis are largely unknown in the majority of solid tumors, including gastric cancer.
  • In this study, we analyzed the correlation between ABI1 expression and the clinicopathological characteristics, tumor progression, and prognosis of patients with gastric carcinoma.
  • Among them 59 tumor tissue samples were matched with normal tissue samples.
  • ABI1 expression in 103 patients was strongly correlated with tumor differentiation, clinical stage, and lymph node status (P < 0.01).
  • Downregulation of ABI1 expression in human gastric carcinoma may play a critical role in tumor progression and in determining patient prognosis.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / physiology. Adenocarcinoma / genetics. Cytoskeletal Proteins / physiology. Neoplasm Proteins / physiology. Stomach Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Line, Tumor. Disease Progression. Down-Regulation. Female. Follow-Up Studies. Gastrectomy. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Prognosis. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Zhonghua Zhong Liu Za Zhi. 1994 Jan;16(1):7-10 [8033753.001]
  • [Cites] Br J Surg. 2002 Nov;89(11):1405-8 [12390382.001]
  • [Cites] Orv Hetil. 2005 Jun 12;146(24):1293-9 [16025998.001]
  • [Cites] Clin Cancer Res. 2008 Mar 15;14(6):1669-77 [18347167.001]
  • [Cites] Eur J Cancer. 2005 Feb;41(3):461-9 [15691647.001]
  • [Cites] Genes Dev. 1998 May 15;12(10):1415-24 [9585502.001]
  • [Cites] FEBS Lett. 2003 Apr 10;540(1-3):195-200 [12681507.001]
  • [Cites] Cell. 2003 Feb 21;112(4):453-65 [12600310.001]
  • [Cites] Cancer. 2000 Feb 15;88(4):921-32 [10679663.001]
  • [Cites] Gastric Cancer. 1998 Dec;1(1):51-56 [11957043.001]
  • [Cites] Curr Cancer Drug Targets. 2004 Jun;4(4):345-54 [15180500.001]
  • [Cites] Carcinogenesis. 2008 Sep;29(9):1717-24 [18453543.001]
  • [Cites] BMC Cancer. 2008 Jan 28;8:25 [18226209.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5237-44 [15289329.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 25;102(4):1098-103 [15657136.001]
  • [Cites] Cancer Res. 1992 Dec 15;52(24):6735-40 [1458460.001]
  • [Cites] Oncologist. 2006 Feb;11(2):136-45 [16476834.001]
  • [Cites] J Biol Chem. 2006 Oct 20;281(42):31290-7 [16899465.001]
  • [Cites] Exp Cell Res. 2005 Nov 1;310(2):463-73 [16182283.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Genes Dev. 1995 Nov 1;9(21):2583-97 [7590237.001]
  • [Cites] Mol Cancer Res. 2007 Oct;5(10):1031-9 [17951403.001]
  • [Cites] Oncogene. 2001 Aug 16;20(36):4926-34 [11526477.001]
  • [Cites] Oncogene. 1997 Jan 16;14(2):233-41 [9010225.001]
  • [Cites] Curr Opin Cell Biol. 2006 Feb;18(1):4-10 [16343889.001]
  • [Cites] J Biol Chem. 2001 Aug 3;276(31):28954-60 [11387320.001]
  • [Cites] Mol Cell Biol. 2000 Oct;20(20):7591-601 [11003655.001]
  • [Cites] Neoplasia. 2001 Mar-Apr;3(2):99-104 [11420744.001]
  • [Cites] Cancer Genet Cytogenet. 2002 Nov;139(1):57-9 [12547160.001]
  • [Cites] CA Cancer J Clin. 2001 Jan-Feb;51(1):15-36 [11577478.001]
  • (PMID = 19554484.001).
  • [ISSN] 1559-131X
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ABI1 protein, human; 0 / Adaptor Proteins, Signal Transducing; 0 / Cytoskeletal Proteins; 0 / Neoplasm Proteins
  •  go-up   go-down


67. Treetipsatit J, Kittikowit W, Zielenska M, Chaipipat M, Thorner PS, Shuangshoti S: Mixed embryonal/alveolar rhabdomyosarcoma of the prostate: report of a case with molecular genetic studies and literature review. Pediatr Dev Pathol; 2009 Sep-Oct;12(5):383-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a 28-year-old male with a prostatic tumor that was excised en bloc and showed a RMS with separate areas of embryonal and solid alveolar morphologies at the light microscopic level.
  • In our case, although the morphology was mixed embryonal/alveolar, at the genetic level this tumor was alveolar in nature.
  • [MeSH-minor] Adult. Humans. Immunohistochemistry. Male. Oncogene Proteins, Fusion / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Rhabdomyosarcoma alveolar.
  • Genetic Alliance. consumer health - Rhabdomyosarcoma embryonal.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19175284.001).
  • [ISSN] 1093-5266
  • [Journal-full-title] Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society
  • [ISO-abbreviation] Pediatr. Dev. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Oncogene Proteins, Fusion; 0 / PAX3-FKHR fusion protein, human
  •  go-up   go-down


68. Taïeb S, Ceugnart L, Bonodeau F, Vanseymortier L, Adenis A: [GIST: imaging findings]. J Chir (Paris); 2008;145 Suppl 3:6S12-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RECIST criteria, which are the standard in assessment of post chemotherapy response in adult's solid tumors, can not be used in targeted therapy: the changes in lesion structures even if case of increasing volume are more specific to assess tumor response.
  • [MeSH-minor] Adult. Aged. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19060843.001).
  • [ISSN] 0021-7697
  • [Journal-full-title] Journal de chirurgie
  • [ISO-abbreviation] J Chir (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


69. Hamada K, Ueda T, Tomita Y, Higuchi I, Inoue A, Tamai N, Myoui A, Aozasa K, Yoshikawa H, Hatazawa J: False positive 18F-FDG PET in an ischial chondroblastoma; an analysis of glucose transporter 1 and hexokinase II expression. Skeletal Radiol; 2006 May;35(5):306-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, in this case, the tumor appeared as a well-defined osteolytic lesion in the ischium on radiographs.
  • MR imaging demonstrated two components in the tumor: a solid one and a multilobular cystic component. (18)F-FDG PET imaging revealed an increased uptake in the ischium.
  • [MeSH-minor] Adult. Biomarkers, Tumor / metabolism. False Positive Reactions. Humans. Male. Positron-Emission Tomography / methods. Radiopharmaceuticals. Tissue Distribution

  • Genetic Alliance. consumer health - Chondroblastoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Virchows Arch. 2004 Jan;444(1):28-35 [13680221.001]
  • [Cites] Cancer. 1988 Jun 1;61(11):2291-304 [2835141.001]
  • [Cites] J Bone Joint Surg Am. 1985 Jun;67(5):748-55 [3997927.001]
  • [Cites] Clin Orthop Relat Res. 1973 Sep;(95):300-12 [4585180.001]
  • [Cites] Semin Musculoskelet Radiol. 2000;4(1):89-101 [11061694.001]
  • [Cites] Am J Roentgenol Radium Ther Nucl Med. 1973 Jun;118(2):464-71 [4712761.001]
  • [Cites] J Leukoc Biol. 1996 May;59(5):639-47 [8656048.001]
  • [Cites] Radiology. 2001 Jun;219(3):774-7 [11376267.001]
  • [Cites] Am J Surg Pathol. 1979 Oct;3(5):449-55 [532862.001]
  • [Cites] Skeletal Radiol. 2004 Aug;33(8):477-80 [15150676.001]
  • [Cites] J Nucl Med. 2002 Apr;43(4):510-8 [11937595.001]
  • [Cites] Nucl Med Biol. 2002 May;29(4):443-53 [12031879.001]
  • [Cites] J Nucl Med. 1991 Apr;32(4):623-48; discussion 649-50 [2013803.001]
  • [Cites] J Nucl Med. 1998 May;39(5):810-5 [9591581.001]
  • [Cites] Cancer Res. 1999 Sep 15;59(18):4709-14 [10493529.001]
  • [Cites] Hum Pathol. 1989 Oct;20(10 ):965-76 [2793161.001]
  • [Cites] Skeletal Radiol. 1997 Jun;26(6):325-53 [9229417.001]
  • [Cites] Skeletal Radiol. 2002 Feb;31(2):88-95 [11828329.001]
  • [Cites] Radiology. 1994 Feb;190(2):467-74 [8284401.001]
  • [Cites] J Nucl Med. 2002 Feb;43(2):173-80 [11850481.001]
  • [Cites] J Biol Chem. 1987 Aug 15;262(23):10965-70 [3301848.001]
  • [Cites] J Bioenerg Biomembr. 1997 Aug;29(4):339-43 [9387094.001]
  • [Cites] Cancer Res. 1996 Mar 1;56(5):1164-7 [8640778.001]
  • (PMID = 16333655.001).
  • [ISSN] 0364-2348
  • [Journal-full-title] Skeletal radiology
  • [ISO-abbreviation] Skeletal Radiol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glucose Transporter Type 1; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; EC 2.7.1.1 / Hexokinase
  •  go-up   go-down


70. Ak G, Metintas M, Metintas S, Yildirim H, Ozkan R, Ozden H: Three-dimensional evaluation of chemotherapy response in malignant pleural mesothelioma. Eur J Radiol; 2010 Apr;74(1):130-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: Measurement of tumor response to chemotherapy in malignant pleural mesothelioma (MPM) is problematic because of non-spherical tumor growth patterns and difficulty in choosing target lesion.
  • In this study, we aimed to determine the effectiveness of tumor volume measurement for evaluating chemotherapy response.
  • Chemotherapy responses were evaluated by computed tomography (CT) using volumetric method, World Health Organization (WHO), and modified Response Evaluation Criteria in Solid Tumor (RECIST).
  • The tumor volume was measured using the Cavalieri principle of stereological approaches.
  • CONCLUSIONS: The most suitable chemotherapy response measurement technique is the volumetric method because of non-spherical tumor growth patterns in MPM.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Treatment Outcome. Tumor Burden / drug effects

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 19268516.001).
  • [ISSN] 1872-7727
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


71. Machado MC, Machado MA, Bacchella T, Jukemura J, Almeida JL, Cunha JE: Solid pseudopapillary neoplasm of the pancreas: distinct patterns of onset, diagnosis, and prognosis for male versus female patients. Surgery; 2008 Jan;143(1):29-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solid pseudopapillary neoplasm of the pancreas: distinct patterns of onset, diagnosis, and prognosis for male versus female patients.
  • BACKGROUND: Solid pseudopapillary neoplasm of the pancreas is a distinctive pancreatic neoplasm with low metastatic potential.
  • METHODS: The medical records of 34 consecutive patients with pancreatic solid pseudopapillary neoplasms between 1990 and 2006 were reviewed.
  • Mean diameter of the tumor was 7 cm.
  • Tumor size tended to be smaller in patients treated in more recent years.
  • Tumor recurred in 2 patients (6%).
  • At the time of diagnosis, age was (x +/- SD) higher among male patients (25 +/- 2 years vs 37 +/- 7 years; P <.05) with no difference in tumor size.
  • There was no correlation between tumor aggressiveness and age of the patient or size of tumor.
  • CONCLUSION: This is the first single center study to demonstrate that solid pseudopapillary neoplasms in male patients have distinct patterns of onset and aggressiveness when compared with female patients.
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / analysis. Child. Female. Follow-Up Studies. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local. Pancreatectomy. Prognosis. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18154930.001).
  • [ISSN] 1532-7361
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


72. Clarke SJ, Boyer MJ, Millward M, Underhill C, Moylan E, Yip D, White S, Childs A, Beale P, Latz J, Suri A, Iglesias JL: A phase I/II study of pemetrexed and vinorelbine in patients with non-small cell lung cancer. Lung Cancer; 2005 Sep;49(3):401-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Phase I objectives include maximum tolerated dose (MTD) and recommended phase II dose determination, and pharmacokinetics of the pemetrexed-vinorelbine doublet in locally advanced or metastatic solid tumor patients (pts).
  • Phase II objectives include tumor response evaluation, efficacy, and toxicity for first-line treatment of advanced NSCLC.
  • Evaluable tumor response was 40%, with intent-to-treat 38%.
  • [MeSH-minor] Adult. Aged. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Creatinine / metabolism. Dietary Supplements. Female. Humans. Male. Maximum Tolerated Dose. Middle Aged. Pemetrexed. Time Factors. Treatment Outcome. Vitamin B 12 / pharmacology

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PEMETREXED .
  • Hazardous Substances Data Bank. CYANOCOBALAMIN .
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. GUANINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15923057.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Phytogenic; 0 / Glutamates; 04Q9AIZ7NO / Pemetrexed; 5V9KLZ54CY / Vinblastine; 5Z93L87A1R / Guanine; AYI8EX34EU / Creatinine; P6YC3EG204 / Vitamin B 12; Q6C979R91Y / vinorelbine
  •  go-up   go-down


73. Navi BB, Reichman JS, Berlin D, Reiner AS, Panageas KS, Segal AZ, DeAngelis LM: Intracerebral and subarachnoid hemorrhage in patients with cancer. Neurology; 2010 Feb 9;74(6):494-501
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To analyze the risk factors, presentation, etiologies, and outcomes of adult cancer patients with intracranial hemorrhage (IH).
  • Sixty-eight percent of patients had solid tumors, 16% had primary brain tumors, and 16% had hematopoietic tumors.
  • Independent predictors of 30-day mortality were not having a primary brain tumor, impaired consciousness, multiple foci of hemorrhage, hydrocephalus, no ventriculostomy, and treatment of increased intracranial pressure.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Multivariate Analysis. Retrospective Studies. Risk Factors. Steroids / therapeutic use. Treatment Outcome. Ventriculostomy. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Neurochir (Wien). 2000;142(9):979-85 [11086806.001]
  • [Cites] Surg Neurol. 2008 Sep;70(3):308-11 [18207523.001]
  • [Cites] Neurosurgery. 2001 Aug;49(2):447-9 [11504122.001]
  • [Cites] Intern Med. 2002 Dec;41(12):1130-4 [12521201.001]
  • [Cites] J Clin Neurosci. 2002 Nov;9(6):637-9 [12604273.001]
  • [Cites] Neurol Clin. 2003 Feb;21(1):167-92 [12690649.001]
  • [Cites] J Neurosurg Sci. 2003 Dec;47(4):201-10; discussion 210 [14978474.001]
  • [Cites] J Neurosurg. 1966 Jun;24(6):1034-56 [5327711.001]
  • [Cites] Stroke. 1973 Nov-Dec;4(6):946-54 [4765001.001]
  • [Cites] Acta Neurol Belg. 1973 Jul-Aug;73(4):241-51 [4358767.001]
  • [Cites] J Neurosurg. 1975 Mar;42(3):338-42 [1167903.001]
  • [Cites] Radiology. 1977 Jul;124(1):109-12 [559323.001]
  • [Cites] Neurology. 1977 Jul;27(7):650-5 [559971.001]
  • [Cites] Zentralbl Neurochir. 1977;38(1):29-42 [579154.001]
  • [Cites] Stroke. 1979 May-Jun;10(3):283-8 [462514.001]
  • [Cites] Acta Neurochir (Wien). 1979;49(1-2):35-45 [230705.001]
  • [Cites] Am J Forensic Med Pathol. 1980 Mar;1(1):29-45 [6263083.001]
  • [Cites] Neurosurgery. 1982 Apr;10(4):437-44 [7099393.001]
  • [Cites] Clin Neurosurg. 1982;29:722-79 [7172574.001]
  • [Cites] Surg Neurol. 1984 Jul;22(1):57-62 [6729692.001]
  • [Cites] Medicine (Baltimore). 1985 Jan;64(1):16-35 [3965856.001]
  • [Cites] Stroke. 1986 Jul-Aug;17(4):590-5 [3526643.001]
  • [Cites] J Neurosurg. 1987 Apr;66(4):536-41 [3031239.001]
  • [Cites] J Neurosurg. 1987 Dec;67(6):852-7 [3316531.001]
  • [Cites] Cancer. 1994 Jan 15;73(2):493-8 [8293418.001]
  • [Cites] J Neurooncol. 1994;22(2):183-7 [7745470.001]
  • [Cites] J Neurol. 1997 Feb;244(2):94-100 [9120503.001]
  • [Cites] Cancer. 1999 Jan 15;85(2):368-74 [10023704.001]
  • [Cites] J Formos Med Assoc. 1999 May;98(5):365-7 [10420706.001]
  • [Cites] Proc R Soc Med. 1954 Aug;47(8):689-93 [13194666.001]
  • [Cites] Can Med Assoc J. 1961 Feb 11;84:303-5 [13724252.001]
  • [Cites] Arch Neurol. 1963 Jun;8:644-61 [14065777.001]
  • [Cites] Lancet. 2005 Jan 29-Feb 4;365(9457):387-97 [15680453.001]
  • [Cites] J Neurosurg. 2005 Jan;102(1 Suppl):31-5 [16206731.001]
  • [Cites] J Neurooncol. 2005 Oct;75(1):57-61 [16215816.001]
  • [Cites] J Neurooncol. 2006 Feb;76(3):257-63 [16158215.001]
  • [Cites] J Neurooncol. 2008 Aug;89(1):55-8 [18408892.001]
  • [Cites] Neuro Oncol. 2008 Jun;10(3):355-60 [18436627.001]
  • [Cites] Stroke. 2001 Apr;32(4):891-7 [11283388.001]
  • (PMID = 20142616.001).
  • [ISSN] 1526-632X
  • [Journal-full-title] Neurology
  • [ISO-abbreviation] Neurology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Steroids
  • [Other-IDs] NLM/ PMC2830918
  •  go-up   go-down


74. Sonis S, Treister N, Chawla S, Demetri G, Haluska F: Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients. Cancer; 2010 Jan 1;116(1):210-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Safety data from 78 solid tumor patients enrolled in 2 Phase 1, multicenter trials of the mTOR inhibitor deforolimus (AP23573, MK-8669) were evaluated.
  • [MeSH-minor] Adult. Aged. Clinical Trials, Phase I as Topic. Female. Humans. Male. Middle Aged. Neoplasms / drug therapy. Stomatitis / chemically induced. TOR Serine-Threonine Kinases

  • Genetic Alliance. consumer health - Oral cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 American Cancer Society.
  • (PMID = 19862817.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Intracellular Signaling Peptides and Proteins; 48Z35KB15K / ridaforolimus; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


75. Yildiz B, Ozdemir F, Cobanoglu U, Kavgaci H, Fidan E, Aydin F: Clear cell hidradenoma of the gluteal region: a case report. Acta Dermatovenerol Croat; 2009;17(2):144-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Clear cell hidradenoma is a rare skin appendage tumor.
  • Under the epidermis, an eosinophilic-cytoplasm, uniform-appearance, oval-round-nucleus, benign tumor with cystic and solid components was detected.
  • [MeSH-minor] Adult. Biopsy. Female. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19595274.001).
  • [ISSN] 1330-027X
  • [Journal-full-title] Acta dermatovenerologica Croatica : ADC
  • [ISO-abbreviation] Acta Dermatovenerol Croat
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Croatia
  •  go-up   go-down


76. Hsiao YH, Huang YL, Kuo SJ, Liang WM, Chen ST, Chen DR: Characterization of benign and malignant solid breast masses in harmonic 3D power Doppler imaging. Eur J Radiol; 2009 Jul;71(1):89-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of benign and malignant solid breast masses in harmonic 3D power Doppler imaging.
  • PURPOSE: The authors assessed the characteristics of benign and malignant solid breast tumors in harmonic three-dimensional (3D) power Doppler imaging and proposed decision models to classify benign and malignant breast tumors.
  • Histogram indices, the vascularization index (VI), flow index (FI) and vascularization-flow index (VFI), were calculated for the intra-tumor and for shells with an outside thickness of 3mm surrounding the breast tumors.
  • RESULTS: The results revealed that the choice of decision model comprised the parameters of patient age, intra-tumor VI, and tumor volume to classify benign and malignant breast tumors.
  • The parameter intra-tumor VI was the choice for all of the histogram indices in differentiating between malignant and benign lesions.
  • CONCLUSION: The decision model, which was composed of patient age, tumor volume and intra-tumor VI, and a cut-off value for intra-tumor VI at the upper end of patient age and tumor volume, was recommended in clinical application.
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Middle Aged. Reproducibility of Results. Sensitivity and Specificity. Young Adult

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18479868.001).
  • [ISSN] 1872-7727
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


77. Numakura K, Tsuchiya N, Habucni T: [A case of retroperitoneal neurofibroma successfully resected laparoscopically]. Hinyokika Kiyo; 2009 Jun;55(6):315-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Computed tomography revealed a heterogenous solid mass, 12 x 7 x 6 cm in diameter, in the anterior renal region, which was suspected to be a benign retroperitoneal tumor.
  • We performed laparoscopic resection of the tumor because of persisting left flank pain.
  • [MeSH-minor] Adult. Female. Humans. Neurofibromatosis 1 / complications. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Neurofibroma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19588861.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 22
  •  go-up   go-down


78. Hayes-Lattin B, Nichols CR: Testicular cancer: a prototypic tumor of young adults. Semin Oncol; 2009 Oct;36(5):432-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Testicular cancer: a prototypic tumor of young adults.
  • Testicular cancer is the most common solid tumor among males in the 20- to 39-year age range.
  • Moreover, testicular cancer has unique biological associations, clinical features, and psychosocial impacts that establish this tumor as a prototypic malignancy of young adults.
  • The concurrent but separate development of staging, prognostic systems, and treatment recommendations between the fields of pediatric and adult oncology highlights the need for increased integration and cooperation across these subspecialties.
  • The high rate of survival, combined with the need for long-term monitoring for relapse or late effects, demonstrates the challenge of delivering longitudinal care in this mobile and active young adult population.

  • Genetic Alliance. consumer health - Testicular cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2001 Mar 15;19(6):1629-40 [11250991.001]
  • [Cites] Br J Cancer. 2000 Dec;83(12):1623-9 [11104556.001]
  • [Cites] South Med J. 1967 Feb;60(2):193-5 [4381022.001]
  • [Cites] Cancer Treat Rep. 1982 Jan;66(1):19-23 [7198012.001]
  • [Cites] Br J Urol. 1983 Dec;55(6):769-73 [6652450.001]
  • [Cites] Cancer. 1984 Oct 1;54(7):1269-75 [6088023.001]
  • [Cites] Cancer. 1985 Apr 15;55(8):1849-54 [2858262.001]
  • [Cites] Ann Intern Med. 1986 Jul;105(1):48-51 [2424354.001]
  • [Cites] N Engl J Med. 1987 Jun 4;316(23):1435-40 [2437455.001]
  • [Cites] J Clin Oncol. 1987 Aug;5(8):1290-4 [3040921.001]
  • [Cites] Cancer. 1989 Oct 1;64(7):1560-7 [2789097.001]
  • [Cites] Cancer. 1991 Jan 1;67(1):28-32 [1845937.001]
  • [Cites] Urol Clin North Am. 1993 Feb;20(1):55-66 [8381998.001]
  • [Cites] Leukemia. 1993 Dec;7(12):1975-86 [8255096.001]
  • [Cites] J Clin Oncol. 1994 Nov;12(11):2284-7 [7964941.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):239-45 [8996148.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):594-603 [9053482.001]
  • [Cites] Lancet. 2005 Jul 23-29;366(9482):293-300 [16039331.001]
  • [Cites] J Clin Oncol. 2006 Dec 10;24(35):5512-8 [17158536.001]
  • [Cites] Ann Oncol. 2007 Feb;18(2):241-8 [17060482.001]
  • [Cites] Crit Rev Oncol Hematol. 2007 Dec;64(3):182-97 [17644403.001]
  • [Cites] J Clin Oncol. 2007 Dec 10;25(35):5603-8 [17998544.001]
  • [Cites] J Clin Oncol. 2009 Jun 10;27(17):2779-86 [19414680.001]
  • [Cites] Cancer. 1999 Nov 15;86(10):2171-83 [10570449.001]
  • [Cites] Ann Oncol. 2002 Feb;13(2):222-8 [11885998.001]
  • (PMID = 19835738.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA136251-01; United States / NCI NIH HHS / CA / L30 CA136251-01
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 33
  • [Other-IDs] NLM/ NIHMS135233; NLM/ PMC2796329
  •  go-up   go-down


79. Ringel F, Cedzich C, Schramm J: Microsurgical technique and results of a series of 63 spheno-orbital meningiomas. Neurosurgery; 2007 Apr;60(4 Suppl 2):214-21; discussion 221-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Periorbital tumor infiltration led to intraorbital resection in 32 cases, and five cases presented a solid intraorbital tumor.
  • Seventy-six percent of patients had tumor residuals, of which 61% were stable and 39% were progressive.
  • Eleven tumor residuals were operated and four were treated by radiation.
  • Two-thirds of tumor rests remained stable during the follow-up period.
  • [MeSH-minor] Adult. Aged. Cranial Nerve Diseases / etiology. Exophthalmos / etiology. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm, Residual / radiotherapy. Neoplasm, Residual / surgery. Orbit / pathology. Orbit / surgery. Postoperative Complications / etiology. Reoperation. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17415156.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


80. Vredenburgh JJ, Desjardins A, Reardon DA, Friedman HS: Experience with irinotecan for the treatment of malignant glioma. Neuro Oncol; 2009 Feb;11(1):80-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant glioma is the most commonly occurring primary malignant brain tumor.
  • Irinotecan, a first-line treatment for metastatic colorectal cancer and an agent with high activity against solid tumors of the gastrointestinal tract, is an inhibitor of topoisomerase I, a critical enzyme needed for DNA transcription.
  • Irinotecan crosses the blood-brain barrier and, in preclinical investigations, has demonstrated cytotoxic activity against central nervous system tumor xenografts.
  • Studies in adult and pediatric patients with recurrent, intractable malignant glioma have evaluated irinotecan as monotherapy and in combination with other agents, including temozolomide, carmustine, thalidomide, and bevacizumab.

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Clin Pharmacol. 2006 Mar;61(3):246-55 [16487217.001]
  • [Cites] Clin Adv Hematol Oncol. 2005 Nov;3(11):843-4 [16491625.001]
  • [Cites] Eur J Cancer. 2006 Mar;42(5):582-8 [16427778.001]
  • [Cites] Neuro Oncol. 2006 Apr;8(2):189-93 [16533878.001]
  • [Cites] Br J Cancer. 2006 Jul 17;95(2):131-8 [16835584.001]
  • [Cites] Cancer Treat Rev. 2006 Nov;32(7):491-503 [16959432.001]
  • [Cites] Clin Cancer Res. 2007 Feb 15;13(4):1253-9 [17317837.001]
  • [Cites] Pediatr Blood Cancer. 2007 Apr;48(4):403-7 [16609952.001]
  • [Cites] Lancet Neurol. 2007 May;6(5):421-30 [17434097.001]
  • [Cites] J Clin Oncol. 2007 Aug 1;25(22):3357-61 [17664483.001]
  • [Cites] Biol Pharm Bull. 2007 Aug;30(8):1400-6 [17666793.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4714-21 [17947718.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4722-9 [17947719.001]
  • [Cites] Cancer. 2008 Mar 1;112(5):1139-46 [18246536.001]
  • [Cites] Clin Cancer Res. 2000 May;6(5):2012-20 [10815927.001]
  • [Cites] Invest New Drugs. 2000 Aug;18(3):275-80 [10958598.001]
  • [Cites] N Engl J Med. 2000 Nov 9;343(19):1350-4 [11070098.001]
  • [Cites] Cancer Res. 2000 Dec 15;60(24):6921-6 [11156391.001]
  • [Cites] Neuro Oncol. 2002 Apr;4(2):102-8 [11916501.001]
  • [Cites] Lancet. 2002 Mar 23;359(9311):1011-8 [11937180.001]
  • [Cites] Am J Clin Oncol. 2002 Apr;25(2):204-8 [11943904.001]
  • [Cites] J Neurooncol. 2002 Jan;56(2):183-8 [11995820.001]
  • [Cites] Clin Cancer Res. 2002 Jul;8(7):2202-9 [12114421.001]
  • [Cites] Oncology (Williston Park). 2002 Aug;16(8 Suppl 7):33-40 [12199631.001]
  • [Cites] Ann Oncol. 2002 Dec;13(12):1841-51 [12453851.001]
  • [Cites] Cochrane Database Syst Rev. 2002;(4):CD003913 [12519620.001]
  • [Cites] Ann Oncol. 2003 Apr;14(4):603-14 [12649109.001]
  • [Cites] Cancer. 2003 May 1;97(9 Suppl):2352-8 [12712456.001]
  • [Cites] Cancer. 2003 May 1;97(9 Suppl):2363-73 [12712458.001]
  • [Cites] Cancer. 2003 May 1;97(9 Suppl):2381-6 [12712460.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):2940-9 [12912940.001]
  • [Cites] Am J Clin Oncol. 2004 Feb;27(1):33-8 [14758131.001]
  • [Cites] Semin Oncol. 2003 Dec;30(6 Suppl 19):4-9 [14765377.001]
  • [Cites] Semin Oncol. 2003 Dec;30(6 Suppl 19):15-8 [14765379.001]
  • [Cites] Neuro Oncol. 2004 Jan;6(1):21-7 [14769136.001]
  • [Cites] Neuro Oncol. 2004 Jan;6(1):44-54 [14769140.001]
  • [Cites] Cancer. 2004 Apr 15;100(8):1750-7 [15073866.001]
  • [Cites] J Clin Oncol. 2004 Apr 15;22(8):1382-8 [15007088.001]
  • [Cites] Neuro Oncol. 2004 Apr;6(2):134-44 [15134628.001]
  • [Cites] Neuro Oncol. 2004 Apr;6(2):145-53 [15134629.001]
  • [Cites] Hematol Oncol Clin North Am. 2004 Oct;18(5):1161-81, x [15474340.001]
  • [Cites] Neurology. 2004 Oct 12;63(7):1281-4 [15477552.001]
  • [Cites] Semin Oncol. 2004 Oct;31(5):635-44 [15497116.001]
  • [Cites] Cancer Res. 1991 Aug 15;51(16):4187-91 [1651156.001]
  • [Cites] Cancer Treat Rev. 1994 Jan;20(1):73-96 [8293429.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1995 Feb;58(2):250-2 [7876865.001]
  • [Cites] Cancer Res. 1996 Feb 15;56(4):783-8 [8631014.001]
  • [Cites] Ann Oncol. 1996 Feb;7(2):205-7 [8777179.001]
  • [Cites] Br J Cancer. 1996 Aug;74(4):537-45 [8761367.001]
  • [Cites] Cancer Chemother Pharmacol. 1997;39(3):187-91 [8996518.001]
  • [Cites] Cancer Chemother Pharmacol. 1997;39(5):417-23 [9054955.001]
  • [Cites] Drug Metab Dispos. 1997 Oct;25(10):1157-64 [9321519.001]
  • [Cites] Int J Cancer. 1997 Nov 27;73(5):707-14 [9398050.001]
  • [Cites] Cancer Res. 1998 Mar 1;58(5):1068-73 [9500473.001]
  • [Cites] Cancer Chemother Pharmacol. 1998;41(6):464-8 [9554590.001]
  • [Cites] Cancer Chemother Pharmacol. 1998;41(6):485-90 [9554593.001]
  • [Cites] Ann Neurol. 1998 Oct;44(4):691-5 [9778271.001]
  • [Cites] Nat Med. 1998 Nov;4(11):1334-6 [9809561.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1516-25 [10334539.001]
  • [Cites] Cancer. 2004 Nov 15;101(10):2293-9 [15476282.001]
  • [Cites] J Clin Oncol. 2004 Dec 1;22(23):4779-86 [15570079.001]
  • [Cites] Cancer. 2005 Jan 15;103(2):329-38 [15558802.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):997-1003 [15758010.001]
  • [Cites] Indian J Exp Biol. 2005 Apr;43(4):313-23 [15875714.001]
  • [Cites] J Nucl Med. 2005 Jun;46(6):945-52 [15937304.001]
  • [Cites] Cancer Lett. 2006 Jan 8;231(1):74-86 [16356833.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):328-31 [16428468.001]
  • [Cites] Oncologist. 2006 Feb;11(2):152-64 [16476836.001]
  • (PMID = 18784279.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Topoisomerase I Inhibitors; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  • [Number-of-references] 80
  • [Other-IDs] NLM/ PMC2718962
  •  go-up   go-down


81. Tabori U, Dome JS: Telomere biology of pediatric cancer. Cancer Invest; 2007 Apr-May;25(3):197-208
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most pediatric leukemias and embryonal solid tumors activate the enzyme telomerase, a specialized reverse transcriptase that adds nucleotide repeats to telomeres.
  • In general, high levels of tumor telomerase expression are associated with unfavorable outcome, although results vary according to tumor type.
  • Telomerase inhibitors have been evaluated in preclinical models of adult cancers, but few studies have been conducted on pediatric cancers.

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17530490.001).
  • [ISSN] 0735-7907
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Enzyme Inhibitors; EC 2.7.7.49 / Telomerase
  • [Number-of-references] 130
  •  go-up   go-down


82. Dritschilo A, Huang CH, Rudin CM, Marshall J, Collins B, Dul JL, Zhang C, Kumar D, Gokhale PC, Ahmad A, Ahmad I, Sherman JW, Kasid UN: Phase I study of liposome-encapsulated c-raf antisense oligodeoxyribonucleotide infusion in combination with radiation therapy in patients with advanced malignancies. Clin Cancer Res; 2006 Feb 15;12(4):1251-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EXPERIMENTAL DESIGN: Patients with advanced solid tumors were treated with LErafAON in a phase I dose escalation study while receiving palliative radiation therapy.
  • Twelve of 17 patients were evaluable for tumor response at completion of treatment; four showed partial response, four showed stable disease, and four experienced progressive disease.
  • [MeSH-minor] Abdominal Pain / etiology. Adult. Aged. Blotting, Western. Combined Modality Therapy / adverse effects. Diarrhea / etiology. Dose-Response Relationship, Drug. Female. Fever / etiology. Gene Expression / drug effects. Humans. Infusions, Intravenous. Leukocytes, Mononuclear / drug effects. Leukocytes, Mononuclear / metabolism. Male. Middle Aged. Pharyngitis / etiology. Proto-Oncogene Proteins c-raf / blood. Proto-Oncogene Proteins c-raf / genetics. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16489081.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA74175; United States / NCRR NIH HHS / RR / M01RR13297
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / LErafAON; 0 / Oligodeoxyribonucleotides; 0 / RNA, Messenger; EC 2.7.11.1 / Proto-Oncogene Proteins c-raf
  •  go-up   go-down


83. Silacci M, Brack SS, Späth N, Buck A, Hillinger S, Arni S, Weder W, Zardi L, Neri D: Human monoclonal antibodies to domain C of tenascin-C selectively target solid tumors in vivo. Protein Eng Des Sel; 2006 Oct;19(10):471-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human monoclonal antibodies to domain C of tenascin-C selectively target solid tumors in vivo.
  • We had previously reported that splice isoforms of tenascin-C containing the extra-domain C are virtually absent in normal adult tissues but are highly abundant in high-grade astrocytomas, with a prominent peri-vascular pattern of expression.
  • The G11 antibody, expressed in scFv and in mini-antibody (SIP) format, as well as a scFv-interleukin-2 fusion protein, was then characterized in quantitative biodistribution studies using mice grafted subcutaneously with U87 gliomas, revealing a selective tumor uptake, with tumor/blood ratios up to 11.8:1 at 24 h.
  • A radioiodinated preparation of SIP(G11) was also investigated in a double tracer study using an orthotopic rat glioma model, confirming the antibody's ability to preferentially localize at the tumor site, with tumor/brain ratios superior to the ones observed with (18)F-fluorodeoxyglucose.
  • These tumor-targeting properties, together with the strong immunohistochemical staining of human tumor sections, indicate that the G11 antibody may be used as a portable targeting moiety for the selective delivery of imaging and therapeutic agents to gliomas and lung tumors.
  • [MeSH-minor] Amino Acid Sequence. Animals. Cell Line, Tumor. Glioma / therapy. Humans. Immunotherapy / methods. Kinetics. Molecular Sequence Data. Peptide Library. Protein Structure, Tertiary. Rats. Recombinant Fusion Proteins / chemistry

  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16928692.001).
  • [ISSN] 1741-0126
  • [Journal-full-title] Protein engineering, design & selection : PEDS
  • [ISO-abbreviation] Protein Eng. Des. Sel.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Peptide Library; 0 / Recombinant Fusion Proteins; 0 / Tenascin
  •  go-up   go-down


84. Guazzoni G, Cestari A, Buffi N, Lughezzani G, Nava L, Cardone G, Balconi G, Lazzeri M, Montorsi F, Rigatti P: Oncologic results of laparoscopic renal cryoablation for clinical T1a tumors: 8 years of experience in a single institution. Urology; 2010 Sep;76(3):624-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The indications for LRC were solid SRMs of the kidney <4 cm in diameter diagnosed on preoperative computed tomography or magnetic resonance imaging as an enhancing mass.
  • The mean tumor size was 2.14 ± 0.86 cm (range 0.5-4).
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • [CommentIn] Urology. 2010 Dec;76(6):1523-4; author reply 1524-5 [21130262.001]
  • [CommentIn] Urology. 2010 Sep;76(3):629; discussion 629-30 [20832613.001]
  • (PMID = 20579705.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


85. Guo CJ, Wang YC, Zhou ZH, Zhu JX, Li ZM, Guo CL: [Curative effect of stereotactic 186Re endocavitary irradiation on cystic craniopharyngioma]. Zhonghua Zhong Liu Za Zhi; 2010 Jul;32(7):548-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Among them 12 patients had a solitary cyst, whereas 7 patients with mixed structure (e.g., a large cyst with a small solid portion).
  • The mean volume of the cystic portion of the tumor before irradiation was 8390 mm(3).
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Cysts / radiotherapy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Stereotaxic Techniques. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Craniopharyngioma.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21029702.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Radioisotopes; 7440-15-5 / Rhenium
  •  go-up   go-down


86. Jung CK, Choi YJ, Lee KY, Bae JS, Kim HJ, Yoon SK, Son YI, Chung JH, Oh YL: The cytological, clinical, and pathological features of the cribriform-morular variant of papillary thyroid carcinoma and mutation analysis of CTNNB1 and BRAF genes. Thyroid; 2009 Aug;19(8):905-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The goal of this study was to determine the clinicopathological features of CMVPTC and whether the tumor can be diagnosed by fine-needle aspiration cytology.
  • METHODS: We retrospectively analyzed the clinical appearance and pathological findings in five patients with CMVPTC and sequenced exon 3 of CTNNB1 and exon 15 of BRAF in tumor tissue.
  • Grossly, all tumors were well-circumscribed, solid or cystic.
  • Immunohistochemically, most tumor cells showed nuclear expression of thyroid transcription factor-1, estrogen and progesterone receptors, and p53; cytoplasmic expression of cytokeratins 7 and 19, vimentin, and bcl-2; and cytoplasmic and nuclear accumulation of beta-catenin and galectin-3.
  • [MeSH-minor] Adolescent. Adult. Biopsy, Fine-Needle. DNA Mutational Analysis. Female. Humans. Male. Medical Oncology / methods. Pedigree. Retrospective Studies. Sequence Analysis, DNA

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19534622.001).
  • [ISSN] 1557-9077
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CTNNB1 protein, human; 0 / beta Catenin; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  •  go-up   go-down


87. Cho YJ, Won JB, Byeon SH, Yang WI, Koh HJ, Kwon OW, Lee SC: A choroidal schwannoma confirmed by surgical excision. Korean J Ophthalmol; 2009 Mar;23(1):49-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histologically, the tumor was composed of a mixture of cellular solid components (Antoni A) and loose myxoid components (Antoni B).
  • The tumor was eventually diagnosed as a schwannoma.
  • In the case of atypical findings for a malignant melanoma, a benign neoplasm should be included in the differential diagnosis.
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging

  • Genetic Alliance. consumer health - Schwannoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ophthalmologica. 2000;214(2):156-60 [10720924.001]
  • [Cites] Ophthalmology. 1981 Dec;88(12):1322-9 [7322483.001]
  • [Cites] Br J Ophthalmol. 1987 Jan;71(1):34-40 [3545285.001]
  • [Cites] Acta Ophthalmol Scand. 2005 Dec;83(6):754-6 [16396657.001]
  • [Cites] Br J Ophthalmol. 1994 May;78(5):397-400 [8025076.001]
  • [Cites] Ophthalmology. 1995 Jun;102(6):918-23 [7777299.001]
  • [Cites] Can J Ophthalmol. 1995 Feb;30(1):37-41 [7780898.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 1988;226(5):443-6 [3192095.001]
  • (PMID = 19337481.001).
  • [ISSN] 2092-9382
  • [Journal-full-title] Korean journal of ophthalmology : KJO
  • [ISO-abbreviation] Korean J Ophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2655748
  • [Keywords] NOTNLM ; Enucleation / Schwannoma / Sclerouvectomy
  •  go-up   go-down


88. Ferrandina G, Bonanno G, Pierelli L, Perillo A, Procoli A, Mariotti A, Corallo M, Martinelli E, Rutella S, Paglia A, Zannoni G, Mancuso S, Scambia G: Expression of CD133-1 and CD133-2 in ovarian cancer. Int J Gynecol Cancer; 2008 May-Jun;18(3):506-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cancer stem cells have been isolated from several solid tumors including prostate, colon, liver, breast, and ovarian cancer.
  • CD133-1 and CD133-2 may be useful in order to select and enrich the population of CD133(+) ovarian tumor cells, which are characterized by a higher clonogenic efficiency and proliferative potential.
  • [MeSH-major] Antigens, CD / metabolism. Biomarkers, Tumor / metabolism. Glycoproteins / metabolism. Neoplasm Invasiveness / pathology. Ovarian Neoplasms / mortality. Ovarian Neoplasms / pathology. Peptides / metabolism
  • [MeSH-minor] Adult. Aged. Cohort Studies. Female. Flow Cytometry. Fluorescent Antibody Technique. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging. Probability. Prognosis. Reference Values. Reverse Transcriptase Polymerase Chain Reaction. Risk Assessment. Sensitivity and Specificity. Survival Analysis

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17868344.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AC133 antigen; 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / Glycoproteins; 0 / Peptides
  •  go-up   go-down


89. Burtin P, Bouché O, Giovannini M, Pelletier M, Conroy T, Ruget O, Arsène D, Milan C, Bedenne L: Endoscopic ultrasonography is an independent predictive factor of prognosis in locally advanced esophageal cancer. Results from the randomized FFCD 9102 study from the Fédération Francophone de Cancérologie Digestive. Gastroenterol Clin Biol; 2008 Mar;32(3):213-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor characteristics and lymph node status were prospectively recorded.
  • RESULTS: In the multivariate analysis, three factors were associated with a poor prognosis: inability to ingest solid food (OR: 1.98; P=0.0008); more than three neoplastic subdiaphragmatic lymph nodes (LN) on EUS (OR: 2.41; P<0.0045) and age>65 (OR: 1.53; P<0.056).
  • [MeSH-minor] Adult. Age Factors. Aged. Chemotherapy, Adjuvant. Deglutition Disorders / complications. Female. France. Humans. Lymphatic Metastasis. Male. Middle Aged. Multivariate Analysis. Prognosis. Prospective Studies. Radiotherapy, Adjuvant

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Gastroenterol Clin Biol. 2008 Mar;32(3):e1-2 [18423928.001]
  • [CommentIn] Gastroenterol Clin Biol. 2008 Mar;32(3):211-2 [18353578.001]
  • (PMID = 18372134.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] France
  •  go-up   go-down


90. Kooby DA, Gillespie T, Bentrem D, Nakeeb A, Schmidt MC, Merchant NB, Parikh AA, Martin RC 2nd, Scoggins CR, Ahmad S, Kim HJ, Park J, Johnston F, Strouch MJ, Menze A, Rymer J, McClaine R, Strasberg SM, Talamonti MS, Staley CA, McMasters KM, Lowy AM, Byrd-Sellers J, Wood WC, Hawkins WG: Left-sided pancreatectomy: a multicenter comparison of laparoscopic and open approaches. Ann Surg; 2008 Sep;248(3):438-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OLP and LLP cohorts were matched by age, American Society of Anesthesiologists, resected pancreas length, tumor size, and diagnosis.
  • Indications were solid lesion in 307 (46%), cystic in 295 (44%), and pancreatitis in 65 (10%) cases.
  • [MeSH-minor] Adult. Aged. Cohort Studies. Female. Humans. Laparoscopy. Male. Middle Aged. Pancreatic Fistula / etiology. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Pancreatic Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18791364.001).
  • [ISSN] 1528-1140
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


91. Heckmann M, Heinrich M, Humke U, Bautz W, Uder M: [Differential diagnosis of focal lesions of the kidney in CT and MRT]. Rontgenpraxis; 2008;56(6):219-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In solid Lesions of the kidney first non-surgical lesions as well as lymphoma, renal infarction and nephritis should be excluded.
  • CT and MRI are exellent for tumor detection.
  • Solid masses should be characterized and the major question to be answered is whether the mass represents a surgical or nonsurgical lesion or if follow-up studies are necessary.
  • [MeSH-minor] Adult. Contrast Media. Diagnosis, Differential. Female. Follow-Up Studies. Gadolinium DTPA. Humans. Kidney Diseases, Cystic / classification. Kidney Diseases, Cystic / diagnosis. Kidney Diseases, Cystic / radiography. Kidney Neoplasms / diagnosis. Kidney Neoplasms / radiography. Lymphoma / diagnosis. Lymphoma / radiography. Male. Polycystic Kidney Diseases / diagnosis. Polycystic Kidney Diseases / radiography. Pyelonephritis / diagnosis. Pyelonephritis / radiography. von Hippel-Lindau Disease / diagnosis. von Hippel-Lindau Disease / radiography

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Kidney Diseases.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19294868.001).
  • [ISSN] 0035-7820
  • [Journal-full-title] Röntgenpraxis; Zeitschrift für radiologische Technik
  • [ISO-abbreviation] Rontgenpraxis
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Contrast Media; K2I13DR72L / Gadolinium DTPA
  • [Number-of-references] 24
  •  go-up   go-down


92. Patnaik AK, Lieberman PH, Erlandson RA, Antonescu C: Hepatobiliary neuroendocrine carcinoma in cats: a clinicopathologic, immunohistochemical, and ultrastructural study of 17 cases. Vet Pathol; 2005 May;42(3):331-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nine tumors were of extrahepatic origin, and one tumor was located in the gall-bladder.
  • The cats were adult and geriatric, and the male : female ratio varied according to tumor group.
  • Histologically, the hepatic neuroendocrine carcinomas had two patterns, one with acinar structures separated by vascular stroma lined by cuboidal or columnar cells and the other solid with groups of anaplastic cells separated by vascular stroma.
  • The composite tumor consisted of both bile duct carcinoma and neuroendocrine carcinoma.
  • The extrahepatic neuroendocrine carcinomas and the gallbladder neuroendocrine carcinoma were characterized by solid sheets or groups of round to oval cells with vascular or fibrovascular stroma.

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15872379.001).
  • [ISSN] 0300-9858
  • [Journal-full-title] Veterinary pathology
  • [ISO-abbreviation] Vet. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


93. Adelstein DJ, Moon J, Hanna E, Giri PG, Mills GM, Wolf GT, Urba SG: Docetaxel, cisplatin, and fluorouracil induction chemotherapy followed by accelerated fractionation/concomitant boost radiation and concurrent cisplatin in patients with advanced squamous cell head and neck cancer: A Southwest Oncology Group phase II trial (S0216). Head Neck; 2010 Feb;32(2):221-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Docetaxel, cisplatin, and fluorouracil induction chemotherapy followed by accelerated fractionation/concomitant boost radiation and concurrent cisplatin in patients with advanced squamous cell head and neck cancer: A Southwest Oncology Group phase II trial (S0216).
  • BACKGROUND: In an effort to optimize nonoperative therapy in patients with locoregionally advanced head and neck squamous cell cancer, the Southwest Oncology Group conducted a phase II trial combining 3-drug taxane-containing induction chemotherapy with accelerated fractionation/concomitant boost radiation and concomitant single-agent cisplatin.
  • METHODS: Two induction courses using docetaxel (75 mg/m(2) on day 1), cisplatin (100 mg/m(2) on day 1), and fluorouracil (1000 mg/m(2)/day continuous intravenous infusion days 1-4) were given, with an interval of 21 days.
  • Patients who were stable or responded to the chemotherapy received definitive accelerated fractionation/concomitant boost radiation with concurrent cisplatin (100 mg/m(2)) on days 1 and 22 of radiation.
  • RESULTS: There were 74 eligible and evaluable patients enrolled between March 1, 2003, and August 15, 2004; 52 (70%) had stage IV disease.
  • At least 1 grade 3-4 toxicity was experienced by 63 patients (85%) during induction.
  • A total of 61 patients completed induction and began concurrent chemoradiotherapy; 50 (68%) completed all planned treatment.
  • At least 1 grade 3-4 toxicity was noted in 53 of the 58 patients (91%) evaluated for toxicity from concurrent chemoradiotherapy.
  • Two patients died during induction, and 2 during chemoradiation.
  • With a median follow-up of 36 months (range, 14-50), the 2-year and 3-year overall survival estimates were 70% and 64%, with 2-year and 3-year progression-free survival estimates of 66% and 61%, respectively.
  • CONCLUSIONS: Three-drug induction chemotherapy followed by accelerated fractionation/concomitant boost radiation and concurrent cisplatin is toxic but feasible within a cooperative group.
  • In this patient cohort with advanced head and neck squamous cell cancer, overall and progression-free survivals were encouraging, justifying further study of this approach.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Wiley Periodicals, Inc.
  • [Cites] Lancet. 2000 Mar 18;355(9208):949-55 [10768432.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Aug 1;48(1):7-16 [10924966.001]
  • [Cites] J Clin Oncol. 2000 Apr;18(8):1652-61 [10764425.001]
  • [Cites] N Engl J Med. 2007 Oct 25;357(17):1705-15 [17960013.001]
  • [Cites] N Engl J Med. 2007 Oct 25;357(17):1695-704 [17960012.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007;69(2 Suppl):S112-4 [17848275.001]
  • [Cites] J Clin Oncol. 2007 Sep 10;25(26):4118-26 [17827462.001]
  • [Cites] Lancet. 2006 Sep 2;368(9538):843-54 [16950362.001]
  • [Cites] J Clin Oncol. 2006 Jun 10;24(17):2624-8 [16763275.001]
  • [Cites] J Clin Oncol. 2006 Feb 1;24(4):593-8 [16380415.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8636-45 [16275937.001]
  • [Cites] Head Neck. 2005 Oct;27(10):843-50 [16161069.001]
  • [Cites] J Clin Oncol. 2005 May 1;23(13):3008-15 [15860857.001]
  • [Cites] Semin Oncol. 2004 Dec;31(6):778-85 [15599855.001]
  • [Cites] J Natl Cancer Inst. 2004 Nov 17;96(22):1647-9 [15547172.001]
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1310-7 [9552031.001]
  • [Cites] J Natl Cancer Inst. 1994 Feb 16;86(4):265-72 [8158680.001]
  • [Cites] N Engl J Med. 1991 Jun 13;324(24):1685-90 [2034244.001]
  • [Cites] Laryngoscope. 1988 Nov;98(11):1205-11 [3054373.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1405-10 [11870186.001]
  • [Cites] J Clin Oncol. 2003 Jan 1;21(1):92-8 [12506176.001]
  • [Cites] N Engl J Med. 2003 Nov 27;349(22):2091-8 [14645636.001]
  • [Cites] N Engl J Med. 2004 May 6;350(19):1937-44 [15128893.001]
  • [Cites] N Engl J Med. 2004 May 6;350(19):1945-52 [15128894.001]
  • (PMID = 19557750.001).
  • [ISSN] 1097-0347
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / N01 CA004919; United States / NCI NIH HHS / CA / U10 CA027057; United States / NCI NIH HHS / CA / CA-68183; United States / NCI NIH HHS / CA / U10 CA004919; United States / NCI NIH HHS / CA / N01 CA035431; United States / NCI NIH HHS / CA / CA-35431; United States / NCI NIH HHS / CA / CA-76447; United States / NCI NIH HHS / CA / U10 CA045560; United States / NCI NIH HHS / CA / U10 CA035128; United States / NCI NIH HHS / CA / CA-37981; United States / NCI NIH HHS / CA / CA032102-32; United States / NCI NIH HHS / CA / CA-46441; United States / NCI NIH HHS / CA / N01 CA032102; United States / NCI NIH HHS / CA / CA-74647; United States / NCI NIH HHS / CA / CA-67663; United States / NCI NIH HHS / CA / CA-14028; United States / NCI NIH HHS / CA / CA-7481; United States / NCI NIH HHS / CA / U10 CA014028; United States / NCI NIH HHS / CA / N01 CA046441; United States / NCI NIH HHS / CA / CA-04919; United States / NCI NIH HHS / CA / CA-16385; United States / NCI NIH HHS / CA / U10 CA074647; United States / NCI NIH HHS / CA / CA-42777; United States / NCI NIH HHS / CA / U10 CA032102-32; United States / NCI NIH HHS / CA / CA-22433; United States / NCI NIH HHS / CA / U10 CA035178; United States / NCI NIH HHS / CA / U10 CA105409; United States / NCI NIH HHS / CA / CA-58658; United States / NCI NIH HHS / CA / CA-12644; United States / NCI NIH HHS / CA / U10 CA032102; United States / NCI NIH HHS / CA / CA-35128; United States / NCI NIH HHS / CA / CA32102; United States / NCI NIH HHS / CA / CA38926; United States / NCI NIH HHS / CA / N01 CA035178; United States / NCI NIH HHS / CA / N01 CA038926; United States / NCI NIH HHS / CA / U10 CA067575; United States / NCI NIH HHS / CA / N01 CA027057; United States / NCI NIH HHS / CA / U10 CA046441; United States / NCI NIH HHS / CA / CA-45560; United States / NCI NIH HHS / CA / U10 CA038926; United States / NCI NIH HHS / CA / U10 CA042777; United States / NCI NIH HHS / CA / U10 CA035431; United States / NCI NIH HHS / CA / CA-35178; United States / NCI NIH HHS / CA / CA-27057; United States / NCI NIH HHS / CA / N01 CA067575; United States / NCI NIH HHS / CA / U10 CA067663; United States / NCI NIH HHS / CA / CA-105409; United States / NCI NIH HHS / CA / CA-67575; United States / NCI NIH HHS / CA / N01 CA045560
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Taxoids; 15H5577CQD / docetaxel; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ NIHMS244651; NLM/ PMC2967367
  •  go-up   go-down


94. Stacchiotti S, Tamborini E, Marrari A, Brich S, Rota SA, Orsenigo M, Crippa F, Morosi C, Gronchi A, Pierotti MA, Casali PG, Pilotti S: Response to sunitinib malate in advanced alveolar soft part sarcoma. Clin Cancer Res; 2009 Feb 1;15(3):1096-104
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The tumor vascular pattern prompted us to use sunitinib malate (SM), a tyrosine kinase inhibitor with antiangiogenic properties.
  • RESULTS: After 3 months, two patients had RECIST (response evaluation criteria in solid tumor) partial response, as well as positron emission tomography response and subjective improvement.
  • [MeSH-minor] Adult. Drug Evaluation. Female. Humans. Male. Middle Aged. Phosphorylation. Protein Kinases / metabolism. Proto-Oncogene Proteins c-akt / metabolism. Receptor Protein-Tyrosine Kinases / metabolism. Receptor, Epidermal Growth Factor / metabolism. Receptors, Platelet-Derived Growth Factor / metabolism. Receptors, Vascular Endothelial Growth Factor / metabolism. Signal Transduction / drug effects. TOR Serine-Threonine Kinases


95. Chu Q, Mita A, Forouzesh B, Tolcher AW, Schwartz G, Nieto A, Soto-Matos A, Alfaro V, Lebedinsky C, Rowinsky EK: Phase I and pharmacokinetic study of sequential paclitaxel and trabectedin every 2 weeks in patients with advanced solid tumors. Clin Cancer Res; 2010 May 1;16(9):2656-65
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I and pharmacokinetic study of sequential paclitaxel and trabectedin every 2 weeks in patients with advanced solid tumors.
  • PURPOSE: This phase I study evaluated the feasibility, safety, pharmacokinetics (PK), and preliminary evidence of anticancer activity of the sequential administration of paclitaxel and trabectedin on an every-2-week schedule in patients with refractory solid malignancies.
  • A patient with soft tissue sarcoma had a complete response and several patients with various refractory solid malignancies showed protracted stable disease as their best response.
  • The manageable toxicities at the MTD, preliminary evidence of antitumor activity, and lack of notable PK drug-drug interactions warrant further disease-directed studies of this regimen in relevant tumor types and settings.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anemia / chemically induced. Area Under Curve. Dioxoles / administration & dosage. Dioxoles / adverse effects. Dioxoles / pharmacokinetics. Dose-Response Relationship, Drug. Drug Administration Schedule. Drug Resistance, Neoplasm. Fatigue / chemically induced. Feasibility Studies. Female. Humans. Infusions, Intravenous. Leukopenia / chemically induced. Male. Metabolic Clearance Rate. Middle Aged. Paclitaxel / administration & dosage. Paclitaxel / adverse effects. Paclitaxel / pharmacokinetics. Tetrahydroisoquinolines / administration & dosage. Tetrahydroisoquinolines / adverse effects. Tetrahydroisoquinolines / pharmacokinetics. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 AACR.
  • (PMID = 20406837.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dioxoles; 0 / Tetrahydroisoquinolines; 114899-77-3 / trabectedin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


96. Madur B, Shet T, Chinoy R: Cytologic findings in infiltrating micropapillary carcinoma and mucinous carcinomas with micropapillary pattern. Acta Cytol; 2007 Jan-Feb;51(1):25-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This group included 27 cases with pure mucinous micropapillary morphology (MUMPC), 8 MUMPC associated with a ductal carcinoma of the IMPC type (MUIDC) and 2 cases of mixed mucinous carcinomas with an MUMPC and a solid variant ofpapillary carcinoma (SVPC) component.
  • However, the IMPC smears revealed numerous singly scattered tumor cells and larger fragments with shrub-like branching and the MUMPC had psammoma bodies.
  • The mixed MUMPC and SVPC showed the classic cytologic features of MUMPC admixed with abundant singly dispersed tumor cells in the background representing the SVPC component.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Ductal, Breast / pathology. Chemotherapy, Adjuvant. Female. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Acta Cytol. 2007 Jan-Feb;51(1):1-2 [17328486.001]
  • (PMID = 17328491.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


97. Jarzembowski JA, Lieberman RW: Pediatric sex cord-stromal tumor with composite morphology: a case report. Pediatr Dev Pathol; 2005 Nov-Dec;8(6):680-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric sex cord-stromal tumor with composite morphology: a case report.
  • A 12-year-old female with developmental delay/mental retardation and a family history of gynecologic cancers presented with nonspecific abdominal complaints and was found to have a 4.5-kg, 25- x 23- x 15-cm pelvic mass with solid and cystic components and associated retroperitoneal and mesenteric lymphadenopathy.
  • Histologically, the tumor exhibited several different morphologic appearances including adult granulosa cell tumor, juvenile granulosa cell tumor (with areas of marked atypia), and Sertoli cell tumor.
  • Immunohistochemically, the tumor was positive for calretinin, MIC-2 (CD99), S100 protein, PGP 9.5, and neuron-specific enolase.
  • Electron microscopy of the Sertoli cell tumor-like areas showed Charcot-Bottcher filaments, a distinguishing feature of Sertoli cells.
  • Together, these findings supported a diagnosis of mixed sex cord-stromal tumor including granulosa cell tumor of adult and juvenile types and intermediate- to high-grade Sertoli cell tumor, with large areas of markedly atypical sex cord-stromal tumor.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16222477.001).
  • [ISSN] 1093-5266
  • [Journal-full-title] Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society
  • [ISO-abbreviation] Pediatr. Dev. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


98. Asioli S, Erickson LA, Righi A, Jin L, Volante M, Jenkins S, Papotti M, Bussolati G, Lloyd RV: Poorly differentiated carcinoma of the thyroid: validation of the Turin proposal and analysis of IMP3 expression. Mod Pathol; 2010 Sep;23(9):1269-78
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The Turin Proposal algorithm defines poorly differentiated carcinoma on the basis of the presence of solid/trabecular/insular growth pattern, absence of conventional nuclear features of papillary carcinoma, and the presence of at least one of the following features: convoluted nuclei, mitotic activity > or =3/10 HPF, or tumor necrosis.
  • IMP3 appears to have diagnostic and prognostic value in many solid tumors, including thyroid carcinomas.
  • We examined a series of follicular-cell carcinomas with prominent solid patterns diagnosed at Mayo Clinic (56 cases) (Rochester, MN, USA) and at the University of Turin (96 cases) (Northern Italy) to validate the Turin consensus criteria defining poorly differentiated carcinoma of the thyroid and to evaluate the prevalence and prognostic behavior of this tumor.
  • Tumor characteristics were similar in the cases from the USA and from Italy except for extensive vascular invasion and a prevalent insular growth pattern (lower the former, higher the latter in the Italian series).
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Female. Humans. Immunohistochemistry. Italy / epidemiology. Kaplan-Meier Estimate. Male. Middle Aged. Mutation. Prevalence. Prognosis. Reverse Transcriptase Polymerase Chain Reaction. United States / epidemiology. Young Adult. ras Proteins / genetics

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20562850.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / IMP3 protein, human; 0 / RNA-Binding Proteins; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


99. Twardowski PW, Smith-Powell L, Carroll M, VanBalgooy J, Ruel C, Frankel P, Synold TW: Biologic markers of angiogenesis: circulating endothelial cells in patients with advanced malignancies treated on phase I protocol with metronomic chemotherapy and celecoxib. Cancer Invest; 2008 Feb;26(1):53-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Animal data indicates the presence of circulating endothelial cells (CEC), tumor-derived activated endothelial cells (AEC) and endothelial cell progenitors (ECP).
  • Bone marrow-derived ECP have been shown to be incorporated into tumor vasculature.
  • Forty-four heavily pretreated patients (20 F; 24 M) with various solid tumors were enrolled.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / blood. Neoplasms / drug therapy. Neoplastic Cells, Circulating / drug effects. Neovascularization, Pathologic. Pyrazoles / administration & dosage. Sulfonamides / administration & dosage
  • [MeSH-minor] Adult. Aged. Celecoxib. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Endothelial Cells. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Flow Cytometry. Humans. Male. Middle Aged. Sensitivity and Specificity. Stem Cells

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CELECOXIB .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18181046.001).
  • [ISSN] 1532-4192
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Pyrazoles; 0 / Sulfonamides; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; JCX84Q7J1L / Celecoxib
  •  go-up   go-down


100. Jariwalla RJ, Gangapurkar B, Nakamura D: Differential sensitivity of various human tumour-derived cell types to apoptosis by organic derivatives of selenium. Br J Nutr; 2009 Jan;101(2):182-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These results indicate intrinsic differences in the sensitivity of human tumour derivatives to selenium-mediated apoptosis, providing experimental support for the development of organic selenium compounds as anti-neoplastic agents against solid tumours displaying selective apoptotic sensitivity to these compounds.
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adolescent. Adult. Animals. Anticarcinogenic Agents / therapeutic use. Apoptosis / drug effects. Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Carcinoma / drug therapy. Carcinoma / pathology. Carcinoma, Hepatocellular / drug therapy. Carcinoma, Hepatocellular / pathology. Cell Line, Tumor. Cell Survival. Colonic Neoplasms / drug therapy. Colonic Neoplasms / pathology. Cysteine / analogs & derivatives. Cysteine / therapeutic use. Epithelial Cells / drug effects. Epithelial Cells / pathology. Female. Humans. Liver Neoplasms / drug therapy. Liver Neoplasms / pathology. Male. Melanoma / drug therapy. Melanoma / pathology. Middle Aged. Neuroectodermal Tumors, Primitive, Peripheral / drug therapy. Neuroectodermal Tumors, Primitive, Peripheral / pathology. Organoselenium Compounds / therapeutic use. Selenocysteine / analogs & derivatives. Selenomethionine / therapeutic use. Skin Neoplasms / drug therapy. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. SELENIUM COMPOUNDS .
  • Hazardous Substances Data Bank. SELENIUM METHIONINE .
  • Hazardous Substances Data Bank. SELENO-(DL)-CYSTEINE .
  • Hazardous Substances Data Bank. CYSTEINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18549510.001).
  • [ISSN] 1475-2662
  • [Journal-full-title] The British journal of nutrition
  • [ISO-abbreviation] Br. J. Nutr.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Antineoplastic Agents; 0 / Organoselenium Compounds; 0 / Selenium Compounds; 0CH9049VIS / Selenocysteine; 964MRK2PEL / Selenomethionine; K848JZ4886 / Cysteine; TWK220499Z / selenomethylselenocysteine
  •  go-up   go-down






Advertisement